Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
i 
 
 
PROTOCOL  #: LC I-LUN-ABR-001 
 
TITLE:  A PILOT ST UDY OF CARBOPLATIN WITH NAB-PACLITAXEL IN PA TIENTS 
WITH ADVANCED  NON-SMALL CELL LUNG CANCER OF SQUAMOUS HISTOLOGY 
 
LAY  TITLE:  A STU DY OF THE  DRUGS CAR BOPLATIN AND ABRA XANE FOR 
PATIENTS WITH LUNG CANCER  
 
Coordinating Sit e: 
Levine Cancer Institut e-Research and Ac ademic Headquarters 
Carolin as Medi cal Center 1021 
Morehead Medical Drive 
Charlotte, NC 28204  
 
Sponsor -Investiga tor: 
Kathryn F. Mile ham, MD 
Levine Cancer Institute  
1021 Mor ehead Medical Drive, Suite 3200  
Charlotte, NC 28204  
Telephon e: (980)  442-0400 
Email:  Kathryn.Mile ham@carolin ashealthcare.org 
 
Co-Sponsor -Investiga tor: 
Edward S. Kim, MD Levine 
Cancer Institute  
1021 Mor ehead Medical Drive, Suite  3100  
Charlotte , NC 28204  
Telephon e: (980)  442-3105 
Email:  Edward.Kim@ carolinashealthcare.org 
 
Statistician:  
                       James Symano wski, PhD  
                                          Levine Cancer Institute  
                                  1100 Blythe Blvd, Office # 1164  
Charlotte, NC 2820 4 
Telephon e: (980)  442-2371 
Email:  James.Symano wski@c arolin ashealthcare.org 
 
Tissue  Procurement: 
Carol Farhangfar, PhD,  MBA 
Levine Cancer Institute  
1021 Mor ehead Medical Drive, Suite  2200  
Charlotte, NC 28204  
Telephon e: (980)  442-3227 
Email:  Carol.Farhangfar@carolin ashealthcare.org 
 
 
 
Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
ii 
 
Central Pathologist:  
James M cDermot t, MD 
Carolin as Patholo gy Group 
Carolin as Medi cal Center 1000 
Blythe Blvd 
Charlotte, NC 28203  
Telephon e: (704)  355-2251 
Email:  James.M cDermott@ carolin ashealthcare.org 
 
Levine Canc er Insti tute-Roper Pathologist:  
George F. Worsham, MD  
Coastal P atholo gy Laboratory 
1128  Lango Av enue 
Charleston, SC  29407  
Email: 
George.Worsham@rsfh.com 
 
Levine Canc er Insti tute-Conco rd Pathologist:  
Tim Wax, MD  
CMC No rthEast P athology Laboratory 920 
Chur ch Str eet, No rth 
Concord, NC 28025  
Email: Tim. Wax@carolin ashealthcare.org 
 
Investigator -Initiated Research Coordinator: 
Melanie Bamb erg, MHA, CCRP 
Levine Cancer Institute 1021 
Morehead Medical Drive 
Charlotte, NC 28204  
Telephon e: (980) 442-2366 
Email: Melanie.Bamberg@carolin ashealthcare.org 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
iii 
  
The study will be  condu cted in complian ce with the  proto col, ICH-GCP and any applicable 
regulato ry requirements.  
 
Confidential 
The information provid ed in this do cument is str ictly confidential and is intend ed sol ely for the 
guidance of the clinical investigation.  R eproduction or  disclosure  of this document  - whether in 
part or in full - to pa rties not asso ciated with the clinical investigation, or  its use for any other 
purpose, without the p rior written consent of t he Sponsor -Investigator is n ot permitted. 
 
Throughout this do cument, symbols indi cating proprietary names (, TM)  are not displ ayed. 
Hence, the appearance of product nam es without th ese symbols d oes not imp ly that these  names 
  are not prot ected.   
Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
iv 
 
 
Commercial ag ents: Carboplatin & Nab-Paclitaxel 
Original Phase 2  / Version 2/ November 11, 2015  
 
 
 
PROTOCOL SU MMARY 
A.  Study Title  A Pilot Stu dy of Carboplatin with N ab-Paclitaxel in P atients with  
Advanced Non-Small C ell Lung Cancer of Squamous Histology  
B.  Indica tion Stage IV non-small cell lung cancer of squamous histology  
C.  Clinical Phase  2 
D.  Summary of 
Rationale ABRAXANE, based on results f rom prior studi es, is a promising  drug 
in squ amous cell carcinoma  of the  lung.  This stu dy will h elp to 
explore  the combin ation of  ABRAXANE and carboplatin  more 
thorou ghly in the  subgroup of  patients who h ad the best response in 
prior studi es as well as determine  whether there are any biom arkers 
which can predict for respons e. 
E.  Study  
Objectives The prim ary objective of this stu dy is to assess the  response r ate of the 
combin ation of  carboplatin with  ABRAXANE in patients with 
advanced non -small cell lung cancer (NSCLC) with squ amous cell 
histolog y. Secondary objectives are to assess the disease control rate, 
duration of  respon se, duration of  disease control, overall surviv al, 
progression -free survival, and the  safety and to xicity profile with this 
regimen. The exploratory objective is to assess b road mol ecular 
profiling. 
F.  Sample Approximately 50 subj ects 
G. Inclusion/ 
Exclusion • Stage IV NSCLC with p redomin antly squamous histology  
• Age ≥ 18 years with ECOG ≤ 1  
• Measurable, biopsy accessible dis ease 
• Subje cts with br ain metastases must be stable  for at least 4 
weeks 
• Adequate live r, kidney, and bone  marrow fun ction 
• Negative serum p regnancy test if female  of child-bearing 
potential  
• Pre-existing  peripheral neuropathy < grade 2 
H. Dosag e/Dosage  
Form, Rout e, 
and Dose 
Regimen Carbopl atin will be  dosed on d ay 1 and ABRAXANE will be  dosed 
(dose  level 0 = 100 mg/m2) on days 1, 8, and 15  of a 21 day cycle for a 
total of 6 c ycles. 
Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
v 
 I. Statistical  
Analysis  Overall response r ate will be calculated as the pe rcent of subjects who  
achieve  CR or PR and the 95% confidence interval will be estimat ed 
using  the Clopp er Pears on method.  Disease control rate will be analyzed 
in a simil ar manner.  For both ov erall response rate, and dise ase control 
rate, the  correlation with b aseline subject and dis ease characteristics, and 
biomarkers will be  evaluated using  logistic regression.  
 
Time -to-event variables will be  analyzed usi ng survival analysis 
methods.  Su rvival rates will be  estimat ed using  Kaplan-Meier 
techniques.  The  correlation with b aseline subj ect and dis ease 
characteristics, and bio markers will be  assess ed using Cox multi ple 
regression models.  
 
Correlation amo ng biom arkers in tissue, blood and between tissue and 
blood will be assess ed.  The associ ation among various continuous and 
discrete bioma rkers will be assess ed first by the exploratory data analysis 
using graphical techniques su ch as the s catter plot m atrix, box plots,  and 
BLiP plot17 . Correlation amo ng continuous bioma rkers will be  
examined by Pearson or Spe arman rank correlation coefficients.   The  
association on dis crete bioma rkers will be t ested by Fisher’s exact test. 
Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
Version -2:  Nov  
vi 
 
 
 
SCHE MA 
 
LCI-LUN-ABR-001: Pilot Study of  Carboplatin with N ab-Paclitax el in Patients with 
Adva nced No n-Small Cell Lung Canc er of Squamous Histology  
 
 
 
 
 
ICF Signed  
 
 
 
Eligibility Inclusion Criteria;  
• Stage  IV NSCLC  with predominantly  squamous  
histology  
• Age ≥ 18 years  
• ECOG  ≤ 1 
• Must have measurable,  biopsy  accessible  disease  
• No prior treatment  for metastatic  disease  
• Brain metastasis must be stable for at least 4 
weeks  
• Adequate  liver, kidney  and bone  marrow  function  
• Negative  serum  pregnancy  test in patients  of 
reproductive  age 
• Less than grade  2 pre-existing  peripheral  
neuropathy  
  
 
 
 
Carboplatin  + 
AUC = 6 
Day 1  
ABRAXANE  
100 mg/m2 
Days  1, 8, 15
 
 
 
21 day cycle  x 6 
 
 
 
Treatment  will be 
discontinued  if: 
disease  progressio n, 
unacceptable  
toxicity,  withdrawn  
consent  or 
completion  of 
treatment.  
 
 
 
End of Treatment  visit 30 days  after last 
dose  for clinical  assessment  including  AEs. 
Follow -up every  6 months  until death  or 
lost to follow-up. 
Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
vii 
  
ABBREVIATIONS  
 
AE Adverse event 
ALT Alanine aminotr ansferase 
AST  Asparate aminotr ansfer ase 
AUC Area under curve 
BSA Body surface area 
BRR Best respon se rate 
CI Confid ence interval 
CPT Cell preparation tube  
CR Compl ete response  
cCR Clinic al complete  response 
CTCAE  Common T erminology  Criteria for Adverse Events 
eCRF  Electronic  case report form 
ECOG  Eastern Coop erative Oncolo gy Group 
EDTA Ethylene diamine  tetraacetic acid 
FEC Fluorou racil- epirubicin hydrochlorid e-cyclopho sphamide 
FDA Food and Drug Administr ation 
GFR Glome rular filtration rate 
HER -2 Hum an epidermal growth factor receptor 2 
IDS Investigational Drug Services 
IRB Institutional R eview  Board 
IV Intravenous  
LCI Levine Cancer Institute  
MTD  Maximum  tolerated dose 
NSCLC Non-small cell lung cancer 
ORR  Overall response r ate 
OS Overall surviv al 
PD Progressive  disease 
PR Partial response  
PFS Progression-free surviv al 
PVC  Polyvinyl chlo ride 
RECIST Response Evaluation Crite ria in Solid Tumors 
SAE  Serious adverse event 
SAR  Suspe cted adverse reaction 
SCC  Squamous cell cancer 
SD Stable  disease 
SI Sponso r-investi gator 
SOP Stand ard operating procedure 
TTP Time-to-progression  
UAP Unanticipated adverse problem 
VEGF Vascular endothelial  growth factor 
VEGFR-2 Vascular endothelial  growth factor receptor-2
Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
viii 
  
TABLE OF  CONTEN TS 
SCHE MA ................................ ................................ ................................ ................................ ........  i 
ABBREVIATIONS  ................................ ................................ ................................ .......................  ii 
TABLE OF  CONT ENTS ................................ ................................ ................................ ............  iii 
1. OBJECTIVES  ................................ ................................ ................................ .................... 1 
1.1. Primary  Objectives ................................ ................................ ................................ ...1 
1.2. Secondary Objectives ................................ ................................ ............................... 1 
1.3. Exploratory Objectives ................................ ................................ ............................ 1 
2. BACKGROU ND ................................ ................................ ................................ ............... 1 
2.1. Non-Small C ell Lung Cancer ................................ ................................ ................... 1 
2.2. ABRAXANE ................................ ................................ ................................ ........... 2 
2.3. Carbopl atin ................................ ................................ ................................ ............... 9 
2.4. Rationale ……………………………………………………………………….. 10  
3. SUBJECT S ELECTI ON ................................ ................................ ................................ .10 
3.1. Accrual ................................ ................................ ................................ ................... 10 
3.2. Inclusion Crit eria..……………………………………………………………….10  
3.3. Exclusion Crit eria …………………………………………………………….  ... 11 
4. INVESTI GATION AL PLAN ................................ ................................ .......................... 12 
4.1. Overall Stu dy Design and Plan  ................................ ................................ .............. 12 
4.2. Registration/Enrollm ent ……………………………………….……………… .. 12 
5. TREATMENT PLAN  ................................ ................................ ................................ ......12 
5.1. Pre-Treatment................................ ................................ ................................ ......... 12 
5.2. Agent Administr ation ................................ ................................ ............................. 15 
5.3. Duration of Therapy ................................ ................................ ............................. ..15 
5.4. Follow-Up ………… ……………………………………………………………. 15 
5.5. Off Stu dy …………… ………………………………………………………….. 16 
6. STU DY PROCED URES  ................................ ................................ ................................ .17 
6.1. Informed Consent  ................................ ................................ ................................ ...17 
6.2. Demogr aphics  and Med ical / Treatment Histo ry ................................ ................... 17 
6.3. Physical Examination ................................ ................................ ............................. 17 
Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
ix 
 6.4. Pregnancy Test ................................ ................................ ................................ .......17 
6.5. Symptoms and To xicities ................................ ................................ ....................... 17 
6.6. Concomitant Medi cations  ................................ ................................ ...................... 17 
6.7. Clinic al Laboratory Tests ................................ ................................ ....................... 18 
6.8. Electrocardiogram ................................ ................................ ................................ ..18 
6.9. Radiolo gy and Tumor Measurements ................................ ................................ ....18 
6.10. Tissue  and Blood-based Biomarkers ................................ ................................ ......18 
6.11. Subse quent Ant i-cancer Therapy and Su rvival Status  ................................ ........... 19 
6.12. Study Calendar ................................ ................................ ................................ .......20 
7. REQUI RED EV ALUATIONS  ................................ ................................ ........................ 21 
7.1. Pre-Treatment Ev aluations ................................ ................................ ..................... 21 
7.2. Treatment Period ................................ ................................ ................................ ....21 
7.3. End of  Therapy ................................ ................................ ................................ ......21 
7.4. Follow-Up/Su rvival P eriod ................................ ................................ .................... 22 
8. DOSING  DELA YS/DO SE MODI FICATIONS  ................................ ............................ 22 
8.1. Dose  Modifi cations for A BRAXANE ................................ ................................ ...22 
8.2. Dose  Modifi cations for  Carboplatin ................................ ................................ ......26 
9. SAFETY DATA COLLECTION, RECOR DING AND REPORTI NG ...................... 26 
9.1. Unanticipated Probl em (UAP) Definition  ................................ .............................. 26 
9.2. Adverse Event (AE) Definition ................................ ................................ .............. 26 
9.3. Suspe cted Adverse Reaction (SAR) Definition  ................................ ..................... 28 
9.4. “Unexpected” D efinition ................................ ................................ ........................ 28 
9.5. “Serious”  and “Life-Threatening”  Definitions  ................................ ...................... 28 
9.6. Serious Adv erse Event (SAE)  Definition  ................................ .............................. 29 
9.7. Safety Reporting  to the  Sponsor ( LCI) …………………………………………. 31 
9.8. Safety Reporting  to the  IRB  ................................ ................................ .................. 32 
9.9. Safety Reporting  to Celgene Corporation ................................ .............................. 32 
10. TREATMENT -RELA TED ADVERSE EVEN TS ................................ ........................ 33 
10.1. Carbopl atin ................................ ................................ ................................ ............. 33 
10.2. ABRAXANE ................................ ................................ ................................ ......... 33 
10.3. Adverse Event Ch aracteristics  ................................ ................................ ............... 35 
11. DATA SA FETY AND MONITORING PLAN  ................................ ............................. 36 
11.1. Safety Monitori ng ................................ ................................ ................................ ..36 
11.2. Data Quality Assu rance ................................ ................................ ......................... 36 
12. MEASURE MENT OF  EFFECT  ................................ ................................ .................... 37 
Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
x 
 12.1. Antitumor E ffect ................................ ................................ ................................ ....37 
13. STATI STICAL DESI GN ................................ ................................ ................................ 40 
13.1. Sample  Size Determination ................................ ................................ .................... 40 
13.2. Analysis Endpoints  ................................ ................................ ................................ 42 
13.3. Analysis Populations  ................................ ................................ .............................. 43 
13.4. Analysis Plan  ................................ ................................ ................................ ......... 43 
14. DRUG DISTRIBUTI ON AND DESTR UCTION  ................................ ......................... 44 
14.1. Supp ly and Distribution  ................................ ................................ ......................... 44 
14.2. Drug Accountabili ty ................................ ................................ ............................... 44 
15. STU DY COMPLETION  ................................ ................................ ................................ 45 
16. RETENTION OF  RECOR DS ................................ ................................ ........................ 46 
17. ETHICAL AND  LEGAL I SSUES………… …………………………………….  ....... 46 
17.1. Ethical and  Legal Cond uct of the  Study ……… ……………………………….. 46 
17.2 Confid entiality …… …………………………………………………………….. 47 
18. PUBLIC ATION  POLICY  ………………… ……………………………………… …..47 
REFEREN CES ................................ ................................ ................................ ............................. 48 
APPENDICES ................................ ................................ ................................ .............................. 50 
Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
1  
  
1. OBJECTIVES  
 
1.1. Primary Objectives 
 
The prim ary objective of this stu dy is to assess the  response r ate of the combin ation of  
carboplatin with  ABRAXANE in patients with adv anced non- small cell lung  cancer 
(NSCLC) with squ amous cell histology.  
 
1.2. Seconda ry Objectives 
 
Secondary objectives are to ass ess the  disease control r ate, duration of  response, 
duration of  disease control, overall surviv al, progression-free surviv al, and the safety 
and to xicity profile with this r egimen. 
 
1.3. Explora tory Objectives 
 
Exploratory objectives are to ass ess bro ad mol ecular profiling. 
 
2. BACKGROU ND 
 
2.1. Non-Small C ell Lung Canc er 
 
Lung cancer is the most common cause of cancer death, both in the  United  States and 
worldwide 1.  In the  United St ates, in the  year 2012, ov er 226,000 n ew cases of lung 
cancer were projected to be  diagnosed  and over 160,000 to die  of the dise ase.1   Once 
lung cancer is di agnosed, outcom es are poor, with on ly 15.9% of patients su rviving  
five years after dia gnosis (http://se er.cancer.gov/statfacts/html/lun gb.htm l). 
 
Squamous cell carcinoma  (SCC) accounts for about 30% of  new cases of lung cancer 
in the  United Sta tes. Until r ecently, patients with SCC and adenocarcinoma  had very 
simil ar overall surviv al; how ever, mo re recent studies h ave shown imp roved outcom es 
for adenocarcinoma relative to SC C.2   This is potential ly due to new tre atment options 
for adenocarcinom a. Several drugs known to be  effective in adenocarcinom a, like  
pemetrexed and bevacizumab,  should not be us ed in SCC, se condary to increased 
toxicity or lack of efficacy. The  stand ard front-line chemoth erapy for SCC is  a 
platinu m-based double t,3 frequently carbopl atin combin ed with a t axane, but ove rall 
surviv al in clinical trials is usu ally less than  one year.3   New tre atment options for  
SCC are needed. 
2 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
  
2.2. ABR AXANE 
 
ABRAXANE for Injectable Susp ension (also known as ABI-007, n ab-paclitaxel, 
paclitaxel protein -bound p articles for injectable  suspension)  is an albumi n-bound fo rm 
of paclitaxel with a  mean particle  size of approximately 130 nanomet ers. Paclitaxel 
exists in the  particles in a no n-crystalline, amorphous st ate. A BRAXANE is supplied as 
a white to yellow, steril e, lyophili zed powd er for r econstitution with 20 mL  of 0.9% 
Sodium  Chloride  Injection, USP  prior  to intr avenous in fusion. E ach sin gle-use vial 
contains  100 mg  of paclitaxel and approximately 900 mg  of human albumin. E ach 
milliliter (mL) of reconstituted suspension cont ains 5 mg  paclitaxel. ABRAXANE is 
free of sol vents.  The active agent in A BRAXANE is paclitaxel. 
 
2.2.1.  Indica tion 
 
In the  United St ates, ABRA XANE for Injectable Suspe nsion (p aclitaxel protein -bound 
particles for injectable  suspension)  is indic ated for the tr eatment of b reast cancer after 
failure of combin ation chemoth erapy for met astatic dise ase or relapse within 6 months 
of adjuvant chemoth erapy. Prior  therapy should h ave includ ed an anthracycline unless 
clinically contraindicated. 
 
On October  11, 2012, t he U.S. Food and D rug Administr ation ( FDA) approved 
ABRAXANE for  use in combin ation with c arbopl atin for  initial treatment of p atients 
with loc ally advanced or metast atic non-small cell lung  cancer who are not candidat es 
for curative surgery or radiation the rapy. 
 
ABRAXANE is  also indi cated for the first-line treatment of p atients with met astatic 
adenocarcinoma  of the  pancreas, in c ombin ation with gemcitabine.  
 
2.2.2.  Introduction 
 
ABRAXANE is a  biologic ally interactive albumi n-bound p aclitaxel combining  a 
protein with a  chemoth erapeutic agent in the p article  form. This composition p rovides a 
novel approach of increasing intra-tumo ral concentrations of the  drug by a receptor-
mediated transport p rocess allowing  transcytosis a cross the  endothelial cell. This 
albumi n-specific r eceptor mediated process involves the binding  of albumin to a  
specific r eceptor (gp60) on the in traluminal endothelial cell memb rane, resulting  in 
activation of  a protein (caveolin-1), whi ch initi ates an inte rnalization process in the 
endothelial  cell throu gh the formation of caveolae, with tr ansport of  the inta ct albumi n-
bound chemoth erapeutic compl ex via th ese caveolae to the  underlying tumor  
interstitiu m. A p rotein spe cifically secreted by the tumor (SPARC) binds albumin, 
allowing  release of the hydrophob ic drug to the  tumor cell memb rane18. ABRAXANE 
is the  first biolo gically interactive nanoparticle  product leveraging this gp- 60/caveolin-
1/caveolae/SPARC p athway to increase intra-tumo ral concentration of  the d rug and 
reducing toxic effects in no rmal tissue.  
3 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
  
2.2.3.  Preclinical Studies with ABR AXANE 
 
Preclinical studies comparing ABRAXANE to Ta xol® (paclitaxel Cremophor® EL 
solvent-based, BMS) demonstr ated low er toxicities, with a  maximum tole rated dose  
(MTD) approximately 50% higher for ABRAXANE compar ed to Taxol. At equ al 
doses the re was less myelosupp ression and imp roved efficacy in a xenograft tumor  
model of human m ammary adenocarcinom a.  At equito xic dos es of p aclitaxel, 
ABRAXANE treated groups show ed more  compl ete regressions, lon ger time to 
recurrence, longer doubling  time, and prolonged survival. At equal dose,  tumor  
paclitaxel area under the curve was 33% higher for A BRAXANE versus so lvent bas ed 
paclitaxel, indicating more effective intr atumo ral accumul ation of ABRAXANE18. 
 
2.2.4.  Clinical Stu dies with ABRAXANE 
 
Every-Three-Week ( Q3W) Schedule  in Metasta tic Breast Can cer 
In a phase I study, the MTD of ABRAXANE was determined to be 300 m g/m2 by 30 
minute in fusion Q3 W, without pr emedication or  G-CSF support.4 No severe 
hypersensitivi ty reactions o ccurred with ABRAXANE despite  the absence of 
premedi cation.  Dos e-limit ing toxicities included s ensory neuropathy, stomatitis, and 
superficial keratopat hy, whi ch occurred at a do se of 375 mg/m2. 
 
Two multi center phase II studi es have evaluated 2  dose levels of A BRAXANE (300 
mg/m2, n=63, and 175 m g/m2, n=43) in p atients with metastatic b reast cancer (Ibrahim 
et al 2005 and Investigator’s Bro chure, respectively). The ov erall response rates in th ese 
2 phase II trials were 40%  (95%  CI 25-54%) for the 175 m g/m2 dose,  and 48%  (95% CI 
35-60%)  for the 300 mg/m2 dose.  Of 39 patients receiving  300 m g/m2 as first-line 
therapy for metastatic b reast cancer, 64% (95% CI 49-79%) respond ed.  This w as 
contrasted with a 45% response rate in similar p atients at the  lower dose lev el. Grade 4 
neutropenia was not ed in 24% of  patients at the  higher dose level, occurred prim arily 
during the first cycle and resolved rapidly. 
 
A Phase I II trial in p atients with m etastatic breast cancer compared ABRAXANE 260 
mg/m2 (n=229) to Taxol 175 m g/m2 (n=225) given Q3 W.5 Efficacy analyses were based 
on the  ITT population. The  ORR w as significantly greater for ABRAXANE th an for  
Taxol for  all patients (33% v 19%,  respectively; P = 0.001 ), patients who re ceived first-
line therapy (42%  v 27%,  respectively; P = 0.029), patients who received second-line or  
greater therapy (27% v 13%,  respectively; P = 0.006), and patients who h ad received 
prior anthra cycline therapy in either  the adjuvant/m etastatic setting (34%  v 18%,  
respectively; P = 0.002) or the m etastatic s etting only (27% v 14%,  respectively; P = 
0.010).  Tumor response  rate was also s ignificantly higher for ABRAXANE than for 
Taxol in p atients with vis ceral dominant lesions (34%  v 19%,  respectively; P = 0.002)  
and in patients aged younger than 65  years (34%  v 19%, respectively; P < 0.001). ORR 
also was greater for  ABRAXANE compar ed with stand ard pa clitaxel in p atients with 
4 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 nonvis ceral dominant le sions (34%  v 19%,  respectively) and in patients   65 years old 
(27% v 19%, respectively), but the  results did not r each statisti cal significance because 
of the small number  of patients in these subsets.  
 
Medi an time to p rogression (TTP) was significantly longer with A BRAXANE th an 
with Taxol for  all patients (23.0  v 16.9 w eeks, respectively; haz ard ratio [HR] = 0.75;  P 
= 0.006 ). 
 
There was a trend for greater median su rvival for all patients tr eated with A BRAXANE 
than with  Taxol (65.0  v 55.7 w eeks, respectively; P = 0.374 ). Althou gh no di fference in 
surviv al was observed in firs t-line p atients, the  difference was statistically significant in 
patients who r eceived ABRAXANE, compa red to T axol, as s econd-line or greater 
therapy (56.4 v 46.7 we eks, respectively; HR =  0.73; P = .024).5 
 
The incidence  of hypersensitivi ty reactions (any grade) was low f or both arms (1% for 
ABRAXANE and 2%  for Taxol). No severe (grade 3 or 4) treatment-related 
hypersensitivi ty reactions o ccurred in a ny of the  patients in the  ABRAXANE group 
despite  the absence of premedi cation. In contrast, grade 3 hypersensitivi ty reactions 
occurred in the  Taxol group d espite  stand ard pr emedication ( chest pain, two p atients; 
allergic reaction, thr ee patients). P er protocol, co rticosteroids and  antihist amines were 
not administ ered routin ely to patients in the ABRAXANE group; ho wever, 
premedi cation was adm inistered for emesis, myalgia/arthralgia, or anorexia in 18 
patients (8 %) in the  ABRAXANE group in 2% of  the tr eatment cycles, wh ereas 224 
patients (>  99%) in the Taxol group r eceived premedication in 95% of  the cycles. 
 
Althou gh the p atients in the ABRAXANE group received an average p aclitaxel dose -
intensity 49% greater than that received by patients in the T axol group,  the in cidence of 
treatment-related grade 4 neutropenia was significantly lower in the  ABRAXANE 
group than in the  Taxol group (9% v 22%,  respectively; P < 0.001 ), with a hi gher mean 
neutrophil n adir (1.67 v 1.31x109/L, respectively; P = 0.046), suggesting that 
polyethylated castor oil m ay have contributed to this t oxicity in patients who r eceived 
stand ard (solvent -based) paclitaxel19. 
 
As expected with a higher dose  of pa clitaxel, treatment-related grade 3 sensory 
neuropathy occurred more f requently in the ABRAXANE arm than in the Taxol arm 
(10%  v 2%, r espectively; P < 0.001 ); how ever, these  episod es imp roved with 
interruption of t reatment to grade 2 or 1 in a medi an 22 d ays and  were easily managed 
with t reatment inte rruption and dose  reduction. By day 28 after its first o ccurrence, the 
numb er of patients with pe rsistent grade 3 sensory neuropathy was the s ame (n = 4) in 
both stu dy arms. No  episod es of motor  neuropathy or grade 4 sensory neuropathy were 
reported in either  group. 
 
The only clinical chemistry value th at was notably different between the two tr eatment 
arms was higher serum glucose  levels in the Taxol–treated patients, who also had a 
5 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 higher incidence  of hyperglycemia reported as an AE compar ed with A BRAXANE–
treated p atients (7% v 1% respectively; P = 0.003 ). 
 
Subgroup  analyses revealed that the s afety profiles of ABRAXANE (n=97) and Taxol (n =30) in 
patients who received  the d rugs as firs t-line the rapy were  simil ar to those  in the  overall stu dy 
population.  In subgroup analyses by age, the reported AEs were  similar in patients < 65 years 
old and p atients  65 years old in both groups. Of the p atients 65 years old, the in ciden ces 
of the  following  AEs were notab ly lower in the A BRAXANE group  (n=30) th an in the  Taxol 
group (n=32): n eutro penia (23%  v 59%,  respectively), leuk openia (10% v 31%, respectively), 
nausea (20%  v 38%,  respectively), hyperglycemia (0% v 19%,  respectively), and flushing  (0% v 
16%,  respectively). These data ind icate no additional s afety concerns for ABRAXANE in 
patients 65 years old comp ared with  younger patients. 
 
Six patients (3 %) in the  ABRAXANE group and eight patients ( 4%) in the stand ard 
paclitaxel group died du ring the stu dy, all as a result of dis ease progression. No 
treatment-related deaths oc curred in the  ABRAXANE group; o ne patient (< 1%) in the  
Taxol group died of multi-organ failure, whi ch was considered by the inv estigator to be 
possibly related to tr eatment but m ay also have been a result of s epsis and/or 
progressive dise ase. 
 
Weekly (QW) for 3 W eeks, E very 4 Weeks Schedule in Metastatic Breast Can cer 
 
Thirty-nine patients w ere enrolled into  a Phase I study of ABRAXANE 
administ ered QW for 3 weeks follow ed by a 1 we ek rest in p atients with advanced solid 
tumor s.6  The MTDs for heavily and lightly pre-treated p atients w ere 100 and 150 
mg/m2 respectively.  Dose limiting  toxicities includ ed grade 4 neutropenia and grade 3 
sensory neuropathy. Premedi cation w as not required, and un expected, non-taxane 
associ ated to xicities were not obs erved. 
 
In a Phase II trial in h eavily pretreated patients with t axane-refractory met astatic b reast 
cancer, objective antitumor  responses o ccurred in 14% of wom en treated with 
ABRA XANE 100 m g/m2 QW schedule. A BRAXANE weekly regim en was well 
tolerated; 91% of  106 p atients w ere treated at the full dose of 100  mg/m2 of 
ABRA XANE without dose r eductions. B ased on the  activity and low to xicity 
document ed with this s chedule, the  study was expanded to ev aluate  the ef ficacy and 
safety/tolerability of a higher dose  of ABRAXANE 125 m g/m2 weekly regimen in 75 
addition al patients. Results of this dose-findi ng study confirm the dose of ABRAXANE 
100 mg/m2 as the appropriate dose  for further study in this pati ent popul ation.7 
 
In an open-label, randomized, multi center phase II study comparing the antitumor  
response and toxicity of two QW dosing  regimens, A BRAXANE dosed  Q3W, and 
Taxotere® (polysorbate solvent -based docetaxel Sanofi-Aventis] Q3W for the first-line 
treatment of met astatic b reast cancer.5 A total of  300 p atients w ere randomized to one 
of four tr eatment arms: (A) ABRAXANE 300 mg/m2 IV Q3W, (n=76); (B) 
6 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 ABRAXANE 100 m g/m2  IV Day 1,8,15  every 28 days (n=76); (C) A BRAXANE 150 
mg/m2 IV Day 1,8,15 every 28 days (n=74); or (D) Taxotere 100 m g/m2 Q3W (n=74). 
The prim ary objective of the  trial was to ev aluate  the antitumor  activity and safety of 
three different ABRAXANE re gimens to determine  the optim al dose and fr equency to 
be used.  Secondary objectives included  the comparisons of each treatment group with 
respect to efficacy and safety, specifically: ABRAXANE to T axotere; ABRAXANE 
QW regimens to ABRAXANE Q3W regimen; and the two dose  levels of QW 
ABRAXANE.  Pati ents received ABRAXANE as a 30-minute  IV infusion without 
premedi cation; T axotere was administ ered as a 60-minute in fusion with co rticosteroid 
premedi cation. T he prim ary efficacy endpoint was ORR assess ed every 8 weeks in all 
treatment arms by using  the RECIST guidelines. T he secondary efficacy endpoints 
included  total response (ORR +  SD >16 w eeks) and PFS. Tumor  response r esults 
underwent an evaluation by the investi gators, as well as an Independent Radiology 
Review  (IRR).  If a pre-set level of congruence was observed between the tumor 
responses d escribed by the in vestigators and the  IRR, only the tumor  response assess ed 
by invest igators was reported. Total of  75% of all patients w ere pos t-menop ausal with a 
mean age of 53.9  years at randomi zation. 
 
Both ORRs and  total response  rates were higher in all ABRAXANE arms compa red to 
the Taxotere arm. The  investigator-reported ORRs w ere 46%, 63%,  74%, and 39 %, for 
arms A, B, C, and  D, respectively. This dif ference was statistically significant for both 
QW dosing  arms of A BRAXANE compar ed with T axotere, (P = 0.002 for  arm B v D, 
and P 
<0.001 for arm C v D). The correspondi ng investi gator-reported total response rates 
were 72%, 83%, 91%  and 69%  for the four arms, r espectively. This diff erence reached 
statistical signifi cance for arms B and C compa red to Taxotere (P = 0.009 for arm B v 
D, and p=0.005  for arm C  v. D). No significant dif ference in ORR was not ed between 
the two w eekly dosing arms (arm B v C, P = 0.24). A significant increase in PFS was 
observed in the  150 mg/m2 QW arm compa red to the  Taxotere arm (14.6  v 7.8 months, 
respectively, P = 0.012, h azard ratio 0.57 ). No si gnificant difference in PFS was found  
between the ABRAXANE 300 m g/m2 Q3W arm and Ta xotere arm (A and D). 
Simil arly, PFS was not si gnificantly different between arms A and C, or arms B  and D.  
 
All th ree ABRAXANE arms d emonst rated a  favorable safety profile when compa red 
with the  Taxotere arm. Toxicity data oc curring in >25%  of patients is summa rized in 
Table II. The most frequent hem atologic adverse event was neutropenia, with 
significantly lower rates of Grade 3/4 n eutrop enia in all ABRAXANE arms (Grade 4, 
5%, 5%,  9%, 75% for arms A, B, C, D,  respectively).  ABRAXANE also had low er 
rates of f ebrile neutropenia (1%, 1%, 1%, 8% for arms A,  B, C, D, r espectively) and 
fatigue (Grade 3, 5%, 0%,  3%, 19% for arms A, B, C, D, respectively) compa red to 
Taxotere. While the in cidence of sensory neuropathy was simil ar in the  ABRAXANE 
and Taxotere arms, the m edian time  to imp rovement in patients with G rade 3 
neuropathy was short er in all three A BRAXANE arms (22, 22, 19 and 37 d ays in a rms 
A, B, C and D, respectively).The ABRAXANE arms demonstr ated imp roved safety and 
7 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 increased efficacy compared with T axotere. All th ree ABRAXANE re gimens produc ed 
lower rates of  neutropenia, f ebrile neutrop enia, and fatigue than Taxotere. 
 
Conti nuous We ekly (QW) Schedule  in Neoadjuvant Br east Cancer 
 
The NSA BP studi ed the  administr ation of  ABRAXANE in a  neoadjuvant  
setting to patients with loc ally advanced breast can cer at a dose of 100 mg/m2 QW for 
12 w eeks, with no br eak.8   Four cycles of  flurouracil- epirub ric hydrochloride -
cyclophosph amide (FEC) were administ ered sequentially based on p atients’  human 
epidermal growth factor receptor (HER2)  status: HER2 n egative patients received FEC-
100 (F: 500 m g/m2, E: 100 m g/m2, C: 500 mg/m2 Q3 weeks) and HER2 positive  
patients received we ekly trastuzumab in addition to FEC-75 (F: 500 mg/m2, E: 75 
mg/m2, C: 500 m g/m2 Q3 weeks). Weekly trastuzumab was permitted during  
ABRAXANE and FEC-75 tre atment at the  discretion of  the investi gator.   T he prim ary 
objective of the  trial was to d etermine  the p atholo gic compl ete response rate (pCR) in 
the breast.  Secondary endpoints included  pCR in breast and no des, clini cal complete  
respon se rate (cCR), 2 -year progression f ree surviv al, and overall surviv al. Sixty- five 
patients w ere evaluable for analyses.  The  therapy was well tolerated, as 63 of  65 
patients received 4 cycles of ABRAXANE with 1 to 3 of  the 12 dos es omitted in 4 
patients. Of the  774 plann ed doses of ABRAXANE, on ly 14 (2%) required dose 
reductions or omissions. The  mean duration of A BRAXANE treatment was 12.3 we eks 
(range 9 to 14 w eeks). The mean dose  intensity was 94.8  mg/m2/w eek (range 72.5 to 
100 m g/m2/w eek). A tot al of 62 p atients w ent on to r eceive at least one  dose of FEC 
with 58 compl eting 4 cycles, which resulted in 88% of  patients who were initiated on 
therapy compl eting all planned chemoth erapy. No g rade 4 or 5 adverse 
events w ere reported du ring the ABRAXANE th erapy. The most frequent grade 2 toxicities 
were fatigue, nausea, sens ory neuropathy, joint pain, and dia rrhea. The  incid ences of grades 2 
and 3 s ensory neuropathy were 11% and 5 %, respectively. The incid ences of grades 2 and 3 
neutrop enia were 6% and 3 %, respectively. Following  12 weeks of  ABRAXANE, a  cCR of 34%  
was not ed. The pCR in br east was 29%,  and for the HER2+ subs et, the pCR  was 58%. The  
authors concluded th at the  administr ation of  ABRAXANE 100 m g/m2 QW x  12 w as both 
effective and tol erable. 
At the time  of this updat e, more  than 20 abstracts and publi cations h ave been presented 
at major oncology confer ences or published  in medical journ als related to ABRAXANE 
QW sch edule in  breast cancer, including compl eted and ongoing studies. 
 
In Metastatic Non-Small Cell Lu ng Cancer 
Phase II trials of  ABRAXANE in lung cancer as monoth erapy 9 and in combin ation 
with c arboplatin10 have shown response rates as high as 39%. Th ese studi es suggested 
that the clinical outcomes  were improved with  weekly ABRAXANE (at 100 m g/m2) 
versus every 3 week ABRAXANE in combination with carboplatin ev ery three  
weeks.10   A ph ase III trial randomi zed patients with NS CLC to r eceive either 
carbopl atin/ A BRAXANE or carboplatin/pa clitaxel.  Carbopl atin w as administe red at 
8 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 an AUC of 6  every 3 weeks, and patients received either ABRAXANE 100 m g/m2 
weekly without pr emedi cation ( n=521) or paclitaxel 200 m g/m2 every three  weeks with 
premedi cation ( n=531). The prim ary endpoint w as overall response  rate, and secondary 
endpoints included p rogression fr ee surviv al and overall surviv al.  The response  rates 
were significantly higher in t he carboplatin/A BRAXANE arm, 33%  vs. 25%  (p- 0.005 ).  
These differences were more pronounced in the  subset of  patients with squ amous cell 
carcinom a: a 41%  respon se rate with A BRAXANE in combin ation with c arboplatin vs. 
24% in the  paclitaxel arm. Toxicities were simil ar between the  two arms, with hi gher 
rates of  grade 3 neutrop enia, n europathy, myalgias, and arthralgias on the p aclitaxel 
arm, and hi gher rates of  grade 3 anemia and thrombo cytopenia on the A BRAXANE 
arm.  M edian progression free survival was 6.3 months in the ABRAXANE group 
versus 5.8 months in the control group (p=0.214). Medi an overall surviv al was 12.1 
months in the  ABRAXANE arm versus  11.2 months in the solv ent-based paclitaxel 
group (p=0.271 ).12   Based on this trial, A BRAXANE is FDA approved in com bination 
with carbopl atin for  front-line treatment of patients with adv anced non-small cell lung 
cancer. 
 
2.3. Carboplatin  
 
Carbopl atin is a common ly used agent in met astatic no n-small cell lung cancer.3 It is 
frequently used in combin ation with oth er chemoth erapeutic agents, including  
paclitaxel,3 docetaxel,13 and gemcitabi ne.14   It will be  dosed according to st andards 
based on ABRA XANE dosing at an AUC of 6, as calculated according to institution al 
standards. 
 
2.4. Rationale 
 
ABRAXANE, based on results f rom prior  studi es discussed above, appears to be a 
promising  drug in squ amous cell carcinoma  of the lung.  In a phase II trial, carbopl atin 
(AUC  of 6 every three  weeks) combi ned with w eekly ABRAXANE at 100 m g/m2 had 
improved response r ates versus a group receiving  carboplatin with every three week 
ABRAXANE (47% vs. 30%).10 Based on this dat a, a dosing schedule of carbopl atin at 
an AUC of 6 on day 1 of a three  week cycle in combin ation with A BRAXANE at 100 
mg/m2 on days 1, 8,  and 15 w as selected for  further study.  In the  phase III study with 
this combin ation, combin ation the rapy with ABRAXANE and carbopl atin pr oduced 
higher response r ates th an paclitaxel and carbopl atin in metastatic non-small cell lung 
cancer (33% vs. 25%, p =0.005 ).  The  difference in response r ate was even more  
dramatic for patients with squ amous cell carcinom a, with 41% respon ding to the 
ABRAXANE/carboplatin combin ation, and on ly 24% respondi ng to the  stand ard 
therapy of paclitaxel/carboplatin.  Progression free and ov erall surviv al were non- 
inferior with ABRAXANE and carbopl atin.12 
 
This stu dy will h elp to explore  this combin ation more  thoro ughly in the  subgroup of  
patients who h ad the best response in p rior stu dies (i.e., p atients with squ amous cell 
9 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 carcinom a), as well as determine  whether there are any biom arkers which can predict 
for response.  
 
3. SUBJECT S ELECTI ON 
 
3.1. Accrual 
 
Approximately 50 subj ects will be  enrolled over an enrollment  period of  24 months  in 
order to accrue 45 evaluable subjects (Section 13.3) . Interim analyses will be  conducted 
after the  enrollment of  subject 15, and 30 evaluable subjects. 
 
3.2. Inclusion Criteria 
 
Subj ects must meet all the following criteria: 
 
• Histolo gically confirmed stage IV no n-small cell lung  cancer with 
predomin antly squamous histolog y. 
• No p rior systemic treatment for  metastatic dis ease.  Patients who h ave 
received prior  adjuvant chemothe rapy for early-stage lung cancer are eligible 
if at least 12 months h ave elapsed between the date of final chemoth erapy 
administr ation and the date  of consent. 
• Patients must h ave measurable dis ease, defined as at least one l esion th at can 
be accurately measured in at least one dim ension  (longest diameter to be  
10 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
  
recorded for  non-nodal lesions and short axis for nod al lesions) as >20 mm 
with conv ention al techniques or as >10 mm with  CT s can, M RI, or calipers by 
clinical exam.  RECIST 1.1 will be us ed to m easure disease per Section 12.  
• Biopsy accessible dis ease. 
• Patients with pr evious radioth erapy as definitive  therapy for locally advanced 
non-small cell lung cancer are eligible, as long as the recurrence is outside  the 
original radiation th erapy port. Definitive r adiation the rapy must h ave been 
compl eted >4 weeks prior to the  date the  informed consent is signed. 
• Age >18 years. 
• ECOG p erformance status  <1. 
• If patient has brain metastasis, the  disease must  be stable  (treated and/or 
asymptomatic ), for at least 4 weeks prior to the first dose of study treatment . 
• Bilirubin  < 1.5 m g/dL. 
• Adequate liver fun ction: AST and ALT < 2.5x upper limit of n ormal, alk aline 
phosph atase < 2.5x upper limit of no rmal, unless bone  metastasis is pr esent 
(<5X upper limit of normal)  in the absence  of liv er metastasis. 
• Adequate bo ne marrow fun ction: Platelets >100,000 cells/mm3 (transfusion 
independent, defined as not receiving platelet transfusions within 7 days prior to 
laboratory sample ). 
•  Hemoglobin > 9.0g/dL, and A NC > 1,500 cells/m m.3 
• Adequate renal function with  creatinine <1.5 mg/dL is recommended . 
• Females of childb earing potential  (defined as a sexually mature woman 
who (1) has not undergone hysterectomy [the surgical removal of the 
uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or 
(2) has not been naturally postmenopausal for at least 24 conse cutive 
months [i.e., has had menses at any time during the preceding 24 
consecutive months] ) must:  
• Either commit to true abstinence * from heterosexual contact (which 
must be reviewed on a monthly basis), or agree to use, and be able to 
comply with, effect ive contraception without interruption, 28 days 
prior to starting IP therapy (including dose interruptions), and while 
on study medication or for a longer period if required by local 
regulations following the last dose of IP  and   
• Negative serum or  urine β-hCG pre gnancy test at screening for 
patients of childb earing potentia l and agree to ongoing pregnancy 
testing after the end of study therapy.  This applies even if the subject 
practices true abstinence* from heterosexual contact . 
•  Sexually active m ales must practice true abstinence * or use an effective 
contraception method during  treatment, during dose interruptions   and for  
six months after compl eting treatment even if he has undergone a successful 
vasectomy .Patients must h ave < Grade 2 pre-existing  peripher al neu ropathy 
(per CTCAE). 
• Abili ty to un derstand and the willingness to si gn a written in formed consent 
11 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 document.  
 
*True abstinence is acceptable when this is in line with the preferred and usual 
lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation, 
symptothermal, post -ovulation methods) and withdrawal are not acceptable 
methods of contraception].  
 
3.3. Exclusion Criteria 
 
Subj ects must not  meet any of the following criteria: 
 
• Received prior  systemic therapy for metastatic dise ase. 
• Receiving  any other  investigational agents. 
• Known hypersensitivi ty to either carbopl atin or A BRAXANE. 
• Uncontroll ed and current illness includin g, but not limited to, on going or active 
infection, symptomatic congestive  heart failure, unst able angina p ectoris, cardi ac 
arrhythmia, or psychiatric  illness/social situations that would  limit compli ance with 
study requirements.  
• Pregnant or b reast feeding. 
• Other active malignancies. 
• Neuropathy ≥ grade 2. 
• Subject has received limited field radiation  for palliation ≤ 2 weeks prior to starting 
study treatment and/or from whom ≥ 30% of the bone marrow was  irradiated.  
 
4. INVESTI GATION AL PLAN  
 
4.1. Milestone Date Definitions  
 
Eligibility date : the date of the last documented criterion that confirmed subject 
eligibility.  
Enrollment date: the date of initiation of carboplatin + abraxane treatment.  
Treatment Discontinuation date : the date the investigator decided to discontinue 
subject from carboplatin + abraxane treatment.  
Off Study date : the date on which the subject is determined to have completed the 
study (see Section 5.5).  
 
4.2. Overall Study D esign and Plan 
 
This is a sin gle center, single arm ph ase II study.  Following  informed consent and 
eligibility check, all subj ects will receive therapy with c arbopl atin and 
ABRAXANE. In the first stage of this study, 15 evaluable (as defined in Section 
13.3) patients will be enrolled. All enrolled subjects will continue with study 
treatment for six cycles, or until progression (radiographic/clinical), unacceptable 
toxicity , investigator discretion, or consent withdrawal. If 3 or more responses are 
12 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 observed in the first stage, an additional 15 evaluable subjects will be enrolled. If a 
total of 7 or more responses are observed in the second stage (of 30 total subjects), a 
final 15 evaluable subjects will be enrolled.  
 
Data from this stu dy will be  collected on  electronic case report forms (eCRFs) and 
stored in the  CTMS.  
 
 
4.3. Registration/Enrollment 
 
Subje cts will be  registered in the  CTMS and assign ed a Study ID. The Study ID 
number will b egin with “LCI” and inc lude a two di git number  sequentially assigned 
to the  subject. (e.g. “LCI01” will be  the Study ID assigned to the  first subje ct.) 
 
 
 
 
5. TREATMENT PLAN  
 
5.1. Pre-Treatment 
 
No p rotocol -related assessments m ay be performed prior  to obtaining  informed 
consent. Baseline assessments will be condu cted according to the  Study Calendar in 
Section 6.12 and Section 7.1.  
 
5.2. Agent Administration 
 
Treatment will be admin istered on an outpatient basis. R eported adverse events and 
potential risks a re described in Section 10. Appropriate dose  modific ations are 
described in Section 8. No inv estigational or comm ercial agents or th erapies other  
than those  described b elow m ay be administ ered with the  intent to tre at the subject's 
malignancy. 
 
5.2.1.  ABR AXANE 
 
Subje cts will receive ABRA XANE intr avenous ly at a dose  of 100 mg/m2 on days 1, 
8 and 15 of  a 21 day cycle. 
 
Premedi cation 
Subje cts do not require  premedi cation p rior to ABRA XANE administr ation, as 
hypersensitivi ty reactions are rar e. Corticosteroids for anti-emetic pu rposes may be 
used per institutional st andards. 
 
Althou gh the solubili zing agents Cremopho r® EL and Tween® 80 have long  been 
impli cated in adverse events in cluding  hypersensitivi ty reactions due  to their 
13 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 detergent-like nature and known ability to indu ce hist amine  release 15, the 
administr ation of  solvent-based taxanes (Taxol and Taxotere) requires 
premedi cation with c orticost eroids and histamine r eceptor blocking agents to 
prevent the  occurrence of hypersensitivi ty reactions. Ho wever, the hypersensitizing 
role of  the taxane molecules thems elves cannot be  ruled out.  
 
In the unlike ly event of a mild hypersensitivi ty reaction, p remedi cation m ay be 
administ ered using the pr emedi cation regim en the institution typically uses for 
solvent based paclitaxel.  In the  rare event of a severe hypersensitivi ty reaction, 
discontinue  ABRAXANE. 
 
Availability  
ABRAXANE will be su pplied as comme rcial drug according to package 
insert parameters and provided by the institution al pharmacy. 
 
Storage  and Stab ility 
Storage: Store  the vials in ori ginal cartons at 20º C to 25º C (68º F  to 
77ºF). Retain in the  original package to prot ect from bri ght light.   
Stabili ty: Unop ened vials  of ABRAXANE are  stable until the d ate indi cated on the  
package when sto red between 20ºC to 25ºC (68ºF to 77º F), in the o riginal package. 
Neither freezing nor refrigeration adversely affects the  stabili ty of the pro duct. 
 
Refer to the  package insert for additional info rmation. 
 
Study Medication  Administrati on 
ABRAXANE is inj ected into a  vein [intravenous ( I.V.) infusion]  over 30 minutes.  
The use of an in-line filter is not recomme nded. Following administration, the 
intravenous line should be flushed with sodium chloride 9 mg/ml (0.9%) solution 
for injection to ensure complete administration of the complete dose, according to 
local practice.  
Reconstit ution and  use of ABRAXA NE 
1. Calculate the subject’s body surface area at the beginning of each 
cycle and if t he weight changes by > 10%,  from baseline weight,  re-
calculate  the total dose  (in mg) to be administ ered by: 
• Total Dose  (mg) = BSA x (study dose mg/m2) 
 
2. Calculate the  total numb er of vials required by: 
•  Total Number  of Vials = Total Dose  (mg) 
100 (mg/vial) 
Round up the numb er of vials to be  reconstituted to the n ext higher 
whole  number  when a fractional numb er of vials is  obtain ed by the 
above  formula  (e.g., if t he total numb er of vials =  4.05 or  4.5, then 5 
14 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 vials would be  reconstit uted). 
 
Using  sterile technique, prepare the vi als for  reconstitution.  
 
3. Swab the rubber stop pers with al cohol.  
4. Aseptically, reconstitute each ABRAXANE vial by injecting 20 mL of 
0.9%  Sodium Chloride  Injection, US P. 
• Slow ly inject the 20 mL of 0.9%  Sodium Chlori de Injection, 
USP, over a minimum of 1 minut e, using  the ste rile syringe 
directing the solution flow  onto the  inside  wall of the vial. 
• DO NOT INJECT the  0.9%  Sodium Chloride  Injection, 
USP solution directly onto the lyophili zed cake as this will 
result in fo aming. 
• Once the inj ection is compl ete, allow the  vial to sit for a 
minimum of 5 (five) minut es to ensu re proper wetting of the 
lyophili zed cake/pow der. 
• Gently swirl  and/or inv ert the vial slow ly for at least 2 
minutes until complete  dissolution of  any cake/powder occurs. 
Avoid generation of  foam.  Rapid a gitation or  shaking will 
result in fo aming. 
• If foaming or clumping  occurs, stand solution f or at least 
15 minutes until fo am subsides.  
• Each ml of  reconstituted p roduct will cont ain 5 mg  of 
paclitaxel. 
5. Calculate the  exact total  dosing  volume  of 5 mg/ml suspension 
required for the subject: 
• Dosing  volume  (ml) = Total dose  (mg) / 5 ( mg/ml) 
6. The reconstituted susp ension should be  milky and homo geneous  
15 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
  
without visible p articul ates.  If particul ates or  settling are visible, the 
vial should be  gently inverted again to ensure complete resuspension 
prior to use.  Discard the r econstituted susp ension if p recipitat es are 
observed. 
7. Once the exact volume of r econstituted ABRAXANE has been 
withdr awn from the vi als, disc ard any excess solution le ft over  in 
accordance with stand ard operating procedures. 
8. Further dilution is not ne cessary. Inject the calculated dosing  volume 
of reconstituted ABRAXANE susp ension  into an empty sterile, 
stand ard PVC  IV bag  using an injection po rt.  Inject perpendicu larly 
into the center of the injection po rt to avoid dislod ging plastic  material 
into the  IV bag. 
9. Administer  the calculated dosing  volume  of reconstitut ed 
ABRAXANE susp ension  by IV infusion over  30 minutes.  The  use of 
in-line filters is not r ecommended because the  reconstituted solution 
may clog the filter. 
 
5.2.2.  Carboplatin  
 
Subje cts will receive carboplatin at an AUC of 6  on day 1 of a 21 day cycle. 
 
Carbopl atin is a stand ard treatment for  NSCLC. Carboplatin is administ ered after 
ABRAXANE by intravenous in fusion ov er 60 minutes with stand ard antiemetics  
per local practice guidelines.  The carbopl atin dose will be  calculated per 
institutional st andards. 
 
5.3. Dura tion of Therapy/Treatment Discontinuation  
 
In the  absence of treatment del ays due to adverse event(s), treatment may continue  
for up to six  cycles or  until one of  the following  criteria applies: 
 
• Disease progression; 
• Intercurrent illn ess that prevents fu rther administ ration of 
treatment; 
• Unacceptable  adverse event(s);  
• Subje ct decides to withd raw consent  for the stu dy therapy ; 
• General or sp ecific changes in the  subject's condition r ender the subject 
unacceptable  for further treatment in the ju dgment  of the  investig ator; 
• Subje ct non-complian ce 
 
Subjects who discontinue their treatment early are still considered to be on -study 
and may continue to participate in study procedures (e.g. labs, scans, foll ow-up). 
16 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
  
5.4. Follow-Up 
 
Subje cts will be  follow ed until de ath, three years of follow -up have occurred  or lost 
to fol low-up following  cessation of tr eatment.  Subjects  (or their family members or 
designees) may be contacted by telephone  or in writing  or during clinic visits a fter 
treatment discontinu ation f or collection of  follow-up data every six months un til 
death or lost to follow -up. Follow-up clinical information  may also be obt ained 
through chart reviews.  Subje cts who dis continu ed treatment for unacceptable 
adverse events will be  follow ed until r esolution or stabil ization of  the adverse event 
according to standard of care procedures.  Subje cts who discontinue tr eatment for 
any reason will continue  follow -up. 
 
5.5. Off-Study  
 
Subjects will be considered off study for any of the following reasons:  
• Completion of 3 years of follow -up from enrollment date  
• Consent withdrawal  
• Determination by Princip al Investigator  
• Lost to follow up  
• Death  
 
Off study subjects will not receive study treatment or partic ipate in any study 
procedures, including data collection.  
 
5.5.1.  Subject Withdrawals  
 
Subjects are defined as withdrawn from the study if they revoke consent for both 
treatment and study procedures or the Investigator withdraws them from the study. 
Subjects must  be withdrawn from the trial for the following reasons:  
 
• Subject withdraws consent from study treatment and study procedures. A 
subject must be removed from the trial at his/her own request. At any time 
during the trial and without giving reason, a subject  may decline to 
participate further. The subject will not suffer any disadvantage as a result.  
• Subject is lost to follow -up after three consecutive months of attempted 
contact.  
 
Subjects may be  withdrawn from the study by the Investigator for the following  
reasons:  
 
• The subject is non -compliant with study drug, study  procedures, or both  
(as determined by the Investigator) ; including the use of anti -cancer 
therapy not prescribed by the study protocol.  
17 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 • Development of an intercurrent illness or situation which  would, in the 
judgment of the Investigator , significantly affect assessments of clinical 
status and trial endpoints.  
 
Any subject  who withdraws themselves or who is withdrawn  from the study by the 
Investigator  will remain under medical supervision until d ischarge or transfer is 
medically acceptable.  
 
In all cases, the reason for withdrawal must be documented  in the subject's medical 
records  and in the CTMS.  Withdrawn subjects are considered to be off -study.  
 
 
5.6  Screen Failures and Subject Replace ments 
 
Enrolled subjects who have discontinued treatment or who have withdrawn after 
receiving their first dose of study drug will not be replaced. A consented subject 
who, for any reason (e.g. failure to satisfy the selection criteria or withdraws 
consent), ter minates participation in the study before receiving first dose of study 
drug is regarded as a “screen failure.” S creen Failures may be replaced.  
 
All screen failures will be tracked in the CTMS.  
 
Note that enrolled subjects who do not meet all of the criteria to be included in the 
efficacy population (defined in Section 13.3) will be included in the safety 
population (defined in Section 13.3).  However, these subjects will not contribute 
to the eva luable population and therefore enrollment of subjects will continue until 
the total expected accrual of evaluable subjects  has been reached.  
 
 
6. STU DY PROCED URES  
 
6.1. Informed Cons ent 
 
Written info rmed consent will be obtain ed from each subj ect prior to un dergoing 
protocol -specific evaluations and prior to re ceiving treatment. Women will be 
couns eled regarding risk of teratogenicity and need to use  contraception throu gh the 
course  of the study.  Men will also be couns eled on the n eed to use contraception 
for all sexual encounte rs. 
 
6.2. Demographics and  Medical/T reatment History  
 
A compl ete medical histo ry will be  obtain ed at baseline, including  smoki ng histo ry. 
Any clinically significant pre -existing  toxicity will also be  documented in the 
medical record and recorded on the  eCRF.  Medical histo ry will be obtained within 
18 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 30 days prior  to the first dose  of stu dy medication. ECOG p erformance status will 
be document ed at baseline. 
 
6.3. Physical Examination 
 
Evaluation by body system, height (pre-treatment only), weight, and  body surface 
area (BSA) will be  document ed in the  medi cal record and recorded on the  eCRF. 
Vital si gns will be recorded and include  temperature, blood pr essure, pulse  rate, 
respiratory rate, and oxygen saturation.  ECOG performance status will be assess ed. 
 
6.4. Pregnan cy Test  
 
A serum or  urine  pregnancy test will be  performed at eligibility screening, within 72 
hours prior  to starting stu dy drug treatment, and  as clini cally indicated for wom en 
of childb earing potential. 
 
6.5. Symptoms and Toxici ties 
 
All adv erse and serious adverse events will be  document ed in the  medi cal record 
and recorded on the  eCRF reg ardless of attribution on an ongoing basis throu ghout 
the study. 
 
6.6. Conc omitant Medications 
 
Any medications oth er than ABRAXANE and carboplatin will be  consid ered a 
concomitant medi cation and dos e, route,  frequency, administr ation and st art/stop  
dates will be do cument ed in the  medi cal record and recorded in the  eCRF. 
 
6.7. Clinical Labo ratory Tests 
 
The blood -based clinical laboratory tests will in clude a compl ete blood  count with 
differential and plat elets, a compl ete metabolic panel (including  sodiu m, potassium, 
chloride, bicarbon ate, BUN, creatinine, glucos e, calcium,  albumin, tot al protein, 
total biliru bin, AST, ALT, alkaline phosph atase), ma gnesium, phosphorus, and 
LDH.  CBC with dif ferential will be obtain ed at baseline and w eekly prior  to each 
dose of ABRAXANE. Addition al labs in cluding  CMP,  LDH, magnesium, and 
phosphorus will be obt ained at baseline and every three  weeks prior to each cycle 
with carbopl atin plus A BRAXANE. CBC with differential, CMP, LDH, 
magnesium, and phosphorus will be repeated at cycle 1, day 1 if baseline labs are 
not within 7 days prior to start of study treatment.  CBC with dif ferential, CMP, 
LDH, magnesium,  and phosphor us will be  obtain ed at end of  treatment assessment.  
Laboratory results will be  recorded on the eCRF. 
 
 
19 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 6.8. Electrocardiogr am 
 
A standard electrocardiogram (E KG/ECG)  will be  required at baseline. 
 
6.9. Radiology a nd Tumor Measurements 
 
A CT (comput ed tomog raphy) scan with cont rast of the chest, pelvis and abdomen 
will be p erformed according to the  schedule outlined in S ection 6. 12. Tumor 
measurements will be  recorded on the  eCRF. 
 
6.10. Tissue  and Bloo d-based  Biomarkers 
 
The rationale for tissue -based biom arker analysis includes the possibili ty of 
identi fying predictive m arkers of benefit from c arboplatin and/or ABRAXANE. 
Biopsi es of tumors from the p rimary lesion and/or  lymph node and/or metastatic 
site will be  collected for exploratory analyses of biomarkers after subj ect 
enrollment, but prior to the first dose  of stu dy drug. Archival tumor  tissue,  for 
which adequate tissue  for biom arker testing on prior biopsies m ay be acceptable, 
will be  obtain ed wh en possible.  Archival tumor tissue must h ave been obt ained 
within the p ast 60 d ays and prior to any treatment and will be  reviewed by the 
Investigator.  If the archive s ample  is of insu fficient quali ty or amount, a  new core 
biopsy will be  required. New biopsi es will be  fresh-frozen, collected and stored in 
the CHS Biospe cimen Reposito ry for batch analysis at the end of  the stu dy. 
 
A baseline blood s ample  will be  collected with additional blood colle cted at the 
subsequ ent time  points a ccording to the  Study Calendar in S ection 6.12, using one ED TA 
10 mL tube and two 9  mL CPT tub es for  blood c ell sep aration and sto rage.  
For invest igational sites  unable to p rocess peripher al blood mononucl ear cells 
(PBMCs), obt ain two EDTA 10 mL tubes on ly. Specimens will be d elivered to the 
CHS Biospe cimen Reposito ry to be processed within one  hour of collection, and 
stored for  batch analysis at the  end of the study. 
 
Levine Cancer Institute  will analyze biom arkers in both tissue  and blood including  
those relative to tr eatment and r esponse  (e.g., immunopheno typing, biom arkers 
related to immune  balance, etc.). The immunology  biom arker analysis will be  
performed in the  Immune  Monitori ng Core Laboratory at Cannon R esearch Center, 
Carolinas Medi cal Center in Cha rlotte, NC (c/o Dr. David Foureau). These studi es 
will be  defined in a future related IRB-approved labo ratory research protocol. 
 
6.11. Subs equent Anti-cancer Therapy and Su rvival  Status 
 
Subje ct’s cancer ther apies and surviv al status following  compl etion of  treatment 
will be  recorded in the  eCRF. 
20 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
  
6.12. Study Cal endar  
 
Required  Procedures Baseline  During  Treatment End of Treatment Follow-Up 
 Within 30 days Every 3 weeks, ± 7 Within 30 days after Every 6 months 
 prior to treatment days, unless the last dose of study until death or lost 
 initiation unless otherwise specified medication unless to follow-up 
 otherwise specified  otherwise specified  
Informed consent X    
Demographics X    
Medical and Treatment Xf 
    
History     
Physical Exam, Vital X X X  
Signs, Oxygen Saturation      
Pregnancy Test 
(serum or urine)a X Within 72 hours 
prior to starting If/when clinically 
indicated   
  study drug and   
  if/when clinically   
  indicated    
Symptoms & Toxicities  X X X  
Concomitant X X X  
Medications     
Laboratory Tests Xb Xb Xb  
EKG/ECG  X    
Radiology & Tumor X X X Xc 
Meas urements  Every 6 weeks, ± 14   
  days   
Biopsy Tissue 
Collecti on for Xd 
Prior to treatment    
Biomarkers initiation    
Blood-based Biomarkers X Xe X  
 Within 30 days Pre-dose on day 1 of   
 prior to treatment treatment cycles    
 initiation 3, and 5.   
Subsequent Anticancer    X 
Therapy     
Survival Status    X 
a: In women of child-bearing  potential 
b: CBC  with differential will be obtained at baseline and weekly prior to each ABRAXANE dose. CMP, LDH, 
magnesium, and phosphorus will be obtained at baseline and every three weeks prior to each cycle of 
carboplatin plus ABRAXANE  dose. CBC with differential, CMP, LDH, magnesium, and phosphorus will be 
repeated at cycle 1, day 1 if baseline labs are not within 7 days prior to start of study treatment . 
CBC/differential, CMP, LDH, magnesium, and phosphorus will be obtained at end of treatment assessment. 
c: Per standard surveillance guidelines, as clinically  
indicated.  
d: See Section  6.10 for tissue collecti on requirements. 
e: Pre-dose on day 1 of treatment cycles 3, and 5 and per Secti on 6.10. 
    f: includes smoking history at baseline only  
21 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 7. REQUI RED EV ALUATIONS  
 
7.1. Pre-Treatment Eval uations 
 
Pre-treatment evaluation  will include  screening (to determine  subject eligibility), 
medi cal histo ry (including smoking history at baseline ), physical examination, vit al signs, 
clinical laboratory tests as described in Section 6, as well as adverse events assessment.  
Fresh or archived tumor biopsies are required prior  to treatment initiation.  Blood 
samples for biom arker testing will be  obtain ed prior  to treatment initiation.  
 
Imaging tests, in cluding compr ehensive  (at least chest, abdom en, and pelvis) contrast-
enhanced CT or MRI aimed at defining the extent of  existing  disease must be  
performed and document ed within 30 d ays prior  to the  first dose  of study the rapy.  An 
EKG/ECG must also be  performed and do cument ed prior  to treatment initiation.  
 
A ne gative pregnancy test for all wom en of childbearing potential must be do cument ed 
before initiating treatment. 
 
Written info rmed consent must be obt ained p rior to any study-specific screening 
evaluations and prior to receiving treatment. 
 
7.2. Treatment Period 
 
Prior  to each on-study infusion, vit al signs and  CBC/dif ferential/plat elets will be 
obtain ed. 
 
Vital signs, w eight measurements, toxici ty, concomitant medi cations  and adverse 
events ass essments, p hysical examination, and labo ratory tests (hematology and 
chemistry profi les) will be p erformed within 7 days of day 1 of each cycle . 
 
Imaging studi es and  tumor response  assessments  will be  repeated every 6 weeks (± 2 
weeks), or as clini cally indicated. 
 
After initiating study treatment (cycle 1 day 1) , blood s amples for biom arker testing will 
be obtained every 6 weeks (± 2 weeks). 
 
7.3. End of Therapy 
 
Every subject will und ergo an end-of-therapy evaluation at the time  it is d etermined that 
he or she is no lon ger eligible to receive stu dy therapy.  End of 
22  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
  
therapy evaluations will include vit al signs, weight measurements, to xicity, 
concomitant medi cations  and adverse events ass essments, p hysical examination, 
and labo ratory tests (hematology and chemistry profiles) as well as imaging studi es 
with tumor  measurements  and blood for  biomarker testing. The end of the rapy 
evaluation must  be compl eted within 30 days after treatment discontinu ation. 
 
7.4. Follow-Up/Su rvival Period 
 
All subj ects will be  follow ed until all tr eatment-related toxicities have resolved, 
returned to ba seline, stabilized, or  are deemed irreversible  according to standard of  
care procedures. 
 
Subje cts may be contacted by telephone or in writing, or  during clinic visits a fter 
treatment dis continu ation f or collection of  follo w-up info rmation approximately 
every 6 months until d eath or lost to follo w-up. Follow-up clinical information m ay 
also be obt ained th rough chart reviews. 
 
Imaging studi es and  tumor assessments  will be  attempted per standard surv eillance 
guidelines  (which may be as frequently as every 6 weeks ± 2 weeks) until 
docum ented progression for  subjects who h ad a compl ete response, p artial response, 
or stable disease, and/or disconti nued stu dy therapy due to toxicity or reasons oth er 
than progressive  disease. 
 
 
 
8. DOSING  DELA YS/DO SE MODI FICATIONS  
 
NCI Common T erminol ogy Crite ria for Adverse Events (CTCAE)  version  4.0 will 
be utilized for  grading toxicities. A copy of the CTCAE Version 4.0 can be 
downlo aded from the  CTEP hom epage 
(http://ct ep.cancer.gov/protocol/D evelopm ent/electroni c_applications/ ctc.htm#ct c_40). 
All adv erse clinical experiences, whether observed by the Investigator or  reported 
by the subj ect, must be recorded, with det ails ab out the duration and int ensity of 
each episod e, the action tak en with respect to the stu dy drug, and the subj ect’s 
outcom e. The Investigator must evaluate each toxicity for its r elationship to the  
study drug and severity. 
 
8.1. Dose  Modifications for ABR AXANE 
 
Mana gement of  severe or intole rable adverse reactions m ay require  dose r eduction 
and/or int erruption of  ABRAXANE. Recomm endations of dose r eduction, 
interruption or  discontinu ation in the  management of  adverse reactions are 
summa rized in T able 1. Clini cal judgment of  the Investigator should  guide the  
mana gement plan of each subj ect based on individual b enefit/risk assess ments. 
23  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
  
Table 1:  Pre-specified dose/s chedule modifications for adverse events r elated to 
ABR AXANE 
 
Dose Level Dose  of ABRAXANE (mg/m2) 
0 100 
-1 75 
-2 50 
 
Recomm endations for  dose reduction, int erruption, or dis continu ation in the  mana gement 
of ABRAXANE-related adverse events are outlined in T able 2.  
 
Table 2:  Criteria for dose  modifications for ABR AXANE-related toxicities 
 
Toxici ty Dose  Modification 
Abno rmal H ematol ogic Function 
• ANC ≤ 1.5 x  109 cells/L and plat elets 
<100 x  109 cells/L 
 
• ANC ≤ 1.0 x  109 cells/L and plat elets < 
75 x 109 cells/L. • Level 0 ABRAXANE dose should not 
be administ ered at the start of each 
cycle unless A NC criteria are met. 
• Subje cts must m eet ANC and  platelet 
criteria for subs equent ABRAXANE 
doses (days 8 and 15). If the ANC and 
platelets are not adequate for treatment 
on D ay 8 and/or 15, the  dose will be 
held and the total cycle length remains 
the same. 
 
Refer to Table  3 for inf ormation on d ose 
reductions and g uidelines for opti mal use 
of growth  factors for hematologic  toxicity. 
Abno rmal H epatic Function 
• AST and ALT < 2.5x upper limit of 
norm al, alk aline phosph atase < 2.5x 
upper limit of n ormal, unl ess bone 
metastasis is pr esent in the absence  of 
liver metastasis. • Maintain  level 0 dose  level (see Table 
1). Hepatic toxicity from taxanes may 
occur but is un common.  Therefore, 
hepatic dysfunction that  occurs while  
the subject is on stu dy should prompt an 
evaluation to d etermine  the cause, 
including  the possibili ty of progressive 
metastatic disease and hepatotoxicity 
from con current medications.  
24  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
  
  
Sensory Neuropathy 
• ≥ Grade 3 
 
 
 
 
 
 
 
 
 
 
 
 
• ≥ Grade 4 • Withhold A BRAXANE. Treatment 
may be resumed  at the next low er dose 
level (see Table 1) in su bsequent cycles 
after the sensory neuropat hy improves 
to Grade 1. The  time to  resolution to  
≤ Grade 1 should be  the adverse event 
duration us ed for adverse event 
reporti ng.  Note:  The investigator may 
elect to dose  modify for Grade  3 
sensory n europath y. 
• Withhold A BRAXANE. Treatment 
may be resumed  at a reduction of  2 
dose levels (Dose  Level -2; see  Table 1) 
in subs equent cycles after the  senso ry 
neuropathy improves to Grade 1. 
Hypersensitivi ty Reactions 
• Minor symptoms su ch as flushin g, skin 
reactions, dyspnea, low er back pain, 
hypotension, or t achycardia. 
• Severe reactions, such as hypotension 
requiri ng treatment, dyspnea requiring 
bronchodil ators, angioedema or 
generalized urticaria. • Tempor arily interrupt ABRAXANE 
infusion according to institutional  
stand ards. 
 
• Immediately discontinue  ABRAXANE 
administr ation and begin aggressive 
symptomatic th erapy. Subje cts who 
experience severe hypersensitivi ty 
reactions to ABRAXANE shou ld not be 
re-initiate tre atment. 
 
It is not re commended to administer 
ABRA XANE to subjects with prior 
hypersensitivity to a tax ane. 
Other toxicities 
• Grade 3, except for  anemia • Treatment should be withheld until 
resolution to grade 1 or baseline if 
baseline was greater than grade 1, then  
reinstituted, if  medi cally appropriate, at 
the n ext low er dose  level (see Table 1). 
25  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
  
G-C SFAdministra tion 
Administ er G-CSF 5 mcg/kg/day (rounded to the  nearest vial size per investigator/ 
institution’s st andard of  care) 24 hours after chemoth erapy and hold 48 ho urs prior 
to the next dose.  
 
Table 3:  Use of G-CSF and Dose  reductions for Hematologic Toxicity 
Toxici ty Occurrence Action to be  Taken 
ANC < 500 cells/m m3 
(nadir count)  with 
neutrop enic fever > 38° C 
OR 
Delay of next cycle due to 
persistent neut ropenia 
(ANC <  1500 cells/m m3) 
OR 
For subjects on weekly 
treatment whose  next 
treatment within the  cycle 
(Day 8 or Day 15) is 
omitt ed due  to pe rsistent 
neutrop enia 
(ANC < 1000 cells/m m3) 
(i.e. ANC still <1000 
cells/mm3 after previous 
week’s omission)  
OR 
Neutrop enia 
< 500 cells/mm3 for > 1 
week 
• Thrombo cytopenia 
Grade 3 or Grade 4 Any 
Occurrence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1st 
Occurrence 
 
Recurrence At the first oc currence of a 
hematolo gical toxicity (as outlin ed in 
the Toxicity column ), the same  dose is 
maintain ed and granulocyte colony- 
stimul ating factor (G-CSF) is given as 
outlined b elow.  In the event that a 
hematolo gical toxicity re-occurs in the 
face of G-CSF, dose reduction to the 
next low er level will be r equired for 
subsequent cycles once ANC is 1500  
cells/mm3. 
 
If G-CSF is given concurrently with 
weekly ABRAXANE, administr ation 
may begin the  day after ABRAXANE is 
given and should stop at least 48 hours 
prior to wh en ABRAXANE is given the 
following  week. 
 
 
 
 
 
• Dose  reduction to next lower level. 
 
 
 
• Dose  reduction to ne xt lower level. 
26 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
  
Concomita nt Medications  
Suppo rtive care, including  but not limited to anti-emetic m edications, m ay be 
administ ered at the discretion of  the investigator.  Concurrent tre atment with 
bisphosphon ates is allow ed.  Erythropoietin m ay be administ ered at the discretion of  the 
Investigator, consistent  with institu tional guidelines.  
 
Caution should be  used when concomitant ly administe ring ABRAXANE with 
inhibito rs (e.g., ketoconazole and other imidazole antifun gals, erythromycin, fluo xetine, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gemfibrozilm cimetidin e, ritonavir, s aquinavi r, indinavi r, and nelfinavir) or induc ers 
(e.g., rifampicin, carbamazepine, ph enytoin, efavirenz, and nevirapine) of either 
CYP2C8 or  CYP3A4.)  
 
8.2. Dose  Modifications for Carboplatin  
 
Dose  modifi cations for  carbopl atin can be made at the Investigator’s discretion in 
accordance with the  package insert and institution al standards. 
 
9. SAFETY DATA COLLECTION, RECOR DING AND REPORTI NG 
 
27 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 Safety assessments will consist of monitoring  and recording all adverse events and 
serious adverse events, the  regular monit oring of hematolo gy, blood c hemistry values, 
and re gular measurement  of vital si gns and the performance  of physical examinations. 
These assessments shou ld be performed within ± 7 d ays of the scheduled day of 
assessment except for  adverse events whi ch will  be evaluated continuous ly throu gh the 
study. Safety and tol erability will be  assess ed according  to the  Common T erminology 
Crite ria for Adverse Events (CTCAE) v ersion 4. 0. All adv erse events (Grades 1 – 5) 
will be  recorded on the  eCRF. 
 
9.1. Unanti cipated Problem (UAP) Definition  
 
An Unanticipated Problem ( UAP) is any incidenc e, experience or outcome that is 
unexpected, given the info rmation  provid ed in research-related documentation ( e.g. 
investigator’s brochure, informed consent), related or possibly related to participation in 
the research  and the stu dy popul ation characteristics that is r elated or possib ly related to 
participation in the research stu dy and plac es the p articip ant at an increased risk.  
 
9.2. Adve rse Event (AE) Definition  
 
An adverse event or adverse experience is any untoward medical occurrence in a stu dy 
subject who is administe red a study drug that does not ne cessarily have a causal 
relationship with this tr eatment.  An adverse event can ther efore be any unf avorable and 
unint ended sign, symptom, or dise ase tempo rally associ ated with the use  of the  study 
drug, whether or not consid ered related to the  study drug. 
Pre-existing  conditions th at increase in frequency or severity or change in nature during  
or as a consequence of use  of a drug in human clinical trials are also consid ered adverse 
events.  Adv erse events may also in clude p re or post-treatment complic ations th at occur 
as a result of protocol-mandated p rocedures (e.g., invasive procedures such  as biopsi es). 
 
Any continuing  medi cal condition or clinically significant laboratory abnormality with an ons et 
date before the first date  of stu dy drug administr ation should be consid ered pre-existing  
and should be  document ed. 
 
An AE does not includ e: 
• Relapse  or progression of the underlying malignant dis ease; how ever, the 
associ ated signs, symptoms, or di agnoses should  be recorded as adverse 
events (e.g., “jaundi ce” due to new  or increasing liver metastases, or “tumor  
pain” or “bone  pain” due  to progressive  disease); 
• Medical or su rgical proc edures (e.g., surgery, endoscopy, tooth extraction, 
transfusion).  The condition  that le ads to the p rocedure is the  adverse event; 
• Situations where an unt oward medical occurrence has not o ccurred (e.g., 
hospitali zation f or elective surgery, soci al and/or convenience 
admissions);  
• Overdose  of either study drug or concomitant me dication without any signs or  
symptoms unless the subject is hospit alized for  observation; and  
28 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 • Pregnancy. (Must be  reported as an SAE.)  
 
Laboratory abnorm alities are usually not re corded as adverse events; ho wever, signs 
and/or symptoms th at are associ ated with laboratory findings requiring stu dy 
withdr awal, dose  modifi cation, or  medi cal intervention ( e.g., anemia r equiri ng 
transfusions or  hyperglycemia requiri ng treatment) or  other abnormal assessments ( e.g., 
ECG, radiographs, vital si gns) must be  recorded as adverse events if th ey meet the 
definition of  an adverse event.  In addition, l aboratory abnorm alities marked as 
clinically significant by the investi gator should also be r ecorded as adverse events in the  
eCRF.  The  investigator will record the most severe grade of the clinically significant 
laboratory abnormality and will evaluate its r elationship to the st udy drug and clinical 
condition if/wh en a clinically significant laboratory abnorm ality occurs. 
 
The relationship to stu dy drug therapy should be  assess ed using  the following 
definitions:  
 
Not R elated:  Evid ence exists that the AE has an etiology  other than the st udy drug 
(e.g., pre-existing  condition, unde rlying disease, intercurrent illn ess, or concomitant 
medication).  This in cludes events th at are consid ered remotely or unlik ely related to 
study drug. 
 
Related:  A tempo ral relationship exists bet wee n the event ons et and administr ation of  the 
study drug.  It cannot be  readily explain ed by the subject’s clinical state, inte rcurrent illness, or  
concomitant the rapies.  In the case of cessation or reduction of  the dose, the event abates or 
resolves and reappears upon r echallenge.  It should be  emphasi zed that ine ffective study drug 
treatment should   not be conside red as causally related in the  context of AE reporting.  
This includ es events th at are consid ered possib ly, probably, or definite ly related to 
study drug. 
 
All adverse events (including event nam e, grade, start/stop d ate and attribu tion) will be  
documented in the m edical record and on the eCRF  for this proto col. 
 
The Investigator is responsible for verifying and providing  source documentation for  all 
adverse events and  assigning the attribution  for each event for  all subjects enrolled on 
the trial. 
 
9.3. Susp ected Adve rse Reaction (SA R) Definition  
 
A SAR is an adverse event in whi ch the re is reasonable possibili ty that the study drug 
caused the adverse event as defin ed by 21 C FR 312.32.  The Investigator is r esponsible 
for judging whether it is a reasonable possibili ty that the stu dy drug caused the adverse 
event. 
 
9.4. “Unexpe cted” Definition 
 
29 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 An AE or SAR is to be  consid ered unexpected if  the event is not listed in the 
investi gator brochure or is not listed in the  severity or specificity observed. 
 
9.5. “Serious” and “ Life-Threatening” Definitions 
 
An AE or SAR is to be  consid ered serious if the  Investigator or Sponsoring  Compa ny 
deems it as su ch and the event results in a ny of the followi ng outcomes:  
 
• Death; 
• Life-threatening situation (subj ect is at imm ediate  risk of  death); 
• Inpatient hospitali zation or prolong ation of  an existing  hospitali zation ( excluding  those 
for study drug administr ation, p rotoco l-related procedures, palli ative or hospi ce care, or 
placement of an indw elling catheter, unless asso ciated with oth er serious events); 
• Persistent or si gnificant dis ability/incapacity; 
• Congenital anom aly/birth defect in the offspring of a subject who r eceived stu dy drug; 
Other:  Important medical events that may not result in death, be immediately life -
threatening, or require hospitalization, may be considered an SAE when, based upon 
appropriate medical judgment,  they may jeopa rdize the subject or may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition. Examples of 
such events are:  
 
o Intensi ve treatment in an emergency room or at home for allergic bronchosp asm; 
o Blood dyscrasias or  convulsions th at do not result in hospitali zation; 
o Developm ent of d rug dependency or drug abuse.  
 
An AE or SAR is to be  consid ered life-threatening if the  Investigator or  Funding 
Compa ny deems it as su ch and the event poses  an immedi ate threat of de ath. 
 
9.6. Serious Adv erse Event (SAE) Definition  
 
A serious adverse event is any untoward medical occurrence that at any dose : 
 
• Results in death,  
• Is life -threatening,  
• Requires inpatient hospitalization or prolongation of existing hospitalization,  
• Results in persistent or significant disability/incapacity, or  
• Is a congenital anomaly/  birth defect  
SAE will be reported to Celgene Corporation within twenty -four (24) hours of LCI 
becoming aware of the event or non -serious adverse drug reactions, as may  be required. 
Any correspondence to the FDA related to adverse event reporting will be 
simultaneously copied to Celgene . 
 
SAEs will be captured from the  time the  subject is en rolled through 30 d ays after the 
date of the last stu dy drug administr ation. SAEs will be follow ed until  clinical recovery 
30 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 is compl ete and laboratory tests ha ve returned to bas eline, until p rogression h as been 
stabilized, or until th ere has been acceptable resoluti on of the event. This m ay at times, 
cause the follo w-up period for SAEs  to be  greater than 30 d ays.  The  above referenced 
30-day time p eriod applies even if the  subject is taken off  study and enrolled onto 
anoth er protocol during  this time p eriod. Simil arly, the Investigator is responsible for 
following  the subj ect duri ng the required follo w-up period even if the  subject lives 
elsewhere or has been released from his or h er care and is being  treated un der another 
service at LCI. 
 
Labo ratory abno rmalities: 
Laboratory abnorm alities that me et the definition of  a serious ad verse event will  
be recorded as such the  eCRF  and reported appropriately. The Investigator will r ecord 
the most sev ere grade of the clinically significant laboratory abnormality and will 
evaluate  its relationship to the stu dy drug and clinical condition if/wh en a clinically 
significant lab oratory abnormality occurs. 
 
Planned hospitaliza tions: 
Elective surgeries that h ave been plan ned prior  to subject enrollment in the  study 
or for conditions e xisting  prior  to stu dy enrollm ent do not n eed to be c aptured as SAEs, 
unless compli cations o ccur or  the conditions a re worse that the  subject’s baseline. They 
should h owever be clearly documented in the  eCRF. 
 
Hospit al admission for  treatment required by the proto col need not be  reported as  
an SAE, unless a  complic ation r esults that fits the 21C FR 312.32 d efinition of  a SAE.  
 
Development of N ew Canc ers: 
Secondary malignancies are defined as new cancers, not tr ansformations or  
progression of  original d isease. 
 
Seconda ry malignan cies during 30 day  time period after treat ment 
discontinu ation 
Any secondary malignancy diagnosed  within 30 d ays of the last dose, r egardless  
of attribution, must be reported as an SAE. T he patholo gy report document ing the n ew 
malignancy should  be retained in the  subject’s research chart and in the medi cal record. 
 
Seconda ry malignan cies after the 30 day  time period after treat ment 
discontinu ation 
Any secondary malignancy diagnosed  greater than 30 d ays after l ast day of study 
drug and tho ught to be  possib ly, probably or definitely related to drug must be r eported 
as an SAE. The patholo gy report do cumenting  the n ew malignancy should be  attached. 
 
Deaths: 
Deaths during 30 day  time period a fter trea tment discontinuation  
Any death, expected or  unexpected, o ccurring within 30 d ays of t he last dose of  
study drug, regardless of attribution, must be reported as an SAE.  
31 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
  
Deaths after the 30 day  time period after trea tment dis continuati on 
Deaths oc curring greater than 30 d ays after last day of study drug and tho ught to 
be possib ly, probably or definite ly related to dr ug must be  reported within  24 hours of  
knowl edge of the event. 
 
Pregnan cies: 
Pregnancies and suspe cted pre gnancies (including a positive  pregnancy test 
regardless of a ge or disease  state) of a  female subject occurring while the  subje ct is in 
treatment, or within 28 d ays of the  subject’s last dose  of stu dy drug, are consid ered 
immedi ately reportable events. A BRAXANE is to be dis continu ed immedi ately. The  pregnancy, 
suspected pregnancy, or positive  pregnancy test must be  report ed as an SAE and reported to 
Celgene Drug Safety immedi ately by facsimil e, or other appropriate method, using  the 
Pregnancy Initial Repo rt Form, or  appro ved equival ent form. The  female subject may be 
referred to an obst etrician-gynecologist (not ne cessarily one with reproductive toxicity 
experience) or anoth er appropriate he althcare prof ession al for further evaluation.  
 
The Investigator will fol low the  female  subject until completion of the pregnancy, and 
must noti fy Celgene Drug Safety immedi ately about the  outcome  of the p regnancy 
(either normal or abnorm al outcome) using the Pre gnancy Follow-up R eport Form, or  
approved equival ent form. 
 
If the out come of  the pregnancy was abnorm al (e.g., spont aneous or th erapeutic 
abortion), the  Investigator should report the abnormal outcome  as an AE. If the 
abnorm al out come m eets any of the  serious criteria, it must be  reported as an SAE 
to Celgene Drug Safety immediately by facsimil e, or oth er appropriate method, 
within 24 hou rs of the  Investigator’s kno wledge of the event usi ng the S AE Report 
Form, or  appro ved equival ent fo rm. 
 
All neon atal deaths th at occur within 28 d ays of b irth sh ould be reported, without re gard 
to causali ty, as SAEs.  In addition, a ny infant de ath after 28 days that the Investigator 
suspects is related to the  in utero exposure  to ABRAXANE should also be reported to 
Celgene Drug Safety immedi ately by facsimil e, or other appropriate method, within 24 
hours of  the Investigator’s kno wledge of the event using  the SAE Repo rt Form, or  
approved equival ent form. 
 
Male Subjects : 
If a female  partner of a male subje ct taking ABRAXANE becomes p regnant, the male  
subject taking ABRAXANE should n otify the Investigator, and the pregnant female  
partner should be  advised to call their  healthcare provid er imm ediately. Male patients 
treated with nab -paclitaxel are advised not to father a child and up  to 6 months after 
treatment.  
 
Overdose : 
32 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 Overdose, as defined for this protocol, refers to ABRAXANE dosing only.   On a per 
dose basis, an overdose is defined as the  following amount over the protocol -specified 
dose of ABRAXANE assigned to a given patient, regardless of any associated adverse 
events or sequelae.  
PO-any amount over the protocol -specified dose  
IV- 10% over the protocol -specified dose    
SC-10% over the  protocol -specified dose  
On a schedule or frequency basis, an overdose is defined as anything more frequent than the 
protocol required schedule or frequency.  
On an infusion rate basis, an overdose is defined as any rate faster than the protocol -
specified rate.  For nab -paclitaxel, an infusion completed in less than 25 minutes may 
increase Cmax by approximately 20%, therefore a nab -paclitaxel infusion completed in 
less than 25 minutes will meet the infusion rate criterion for an overdose.   Complete 
data abo ut drug administration, including any overdose, regardless of whether the 
overdose was accidental or intentional, should be reported in the case report form.  
Celgene Drug Safety Contact Information:  
Celgene  Corporation       
Global Drug Safety and  Risk Management     
Connell  Corporate  Park      
300 Connell Dr.   Suite 6000      
Berkeley Heights, NJ   07922         
Fax: (908) 673 -9115  
E-mail: drugsafety@celgene.com  
  
 
Questionable events: 
Any suspected adverse re action can and should be  reported as an SAE if deem ed 
appropriate by the Investigator. 
 
All SAEs (in cluding  event nam e, grade, start/stop d ate and attribution) will be 
document ed in the  medi cal record and on  the eCRF. 
 
The Investigator is responsible for verifying and providing  source documentation for  all 
SAEs and assigning the attribution f or each event for  all subj ects enrolled on the t rial. 
 
9.7. Safety Reporting to the Sponsor (Levine Canc er Insti tute) 
 
All ev ents oc curring during the condu ct of the  study and meeting the definitions of  a UAP or 
SAE will be  report ed prompt ly to the  Sponso r, but no l ater than 2 busin ess days from the  time 
33 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 the Investigator learns of the  event. Appli cable events must be  reported via  the CTMS  with a 
notific ation to the  Proto col Coordin ator and Sponsor -Investigator. 
Deviations involving  the informed consent process or subj ect safety will be r eported 
promptly to the  Sponsor, but no lat er than 5 busin ess days from the  time the  Investigator 
learns of the event. Appli cable events must be reported via the CTMS with a 
notific ation to the  Proto col Coordin ator and Sponso r-Investigator. 
 
9.8. Safety Reporting to the IRB 
 
All ev ents oc curring during the condu ct of a  protocol and m eeting the definition of  an 
UAP or SAE  will be reported to the  IRB promptly, but no l ater than 2 weeks from the  
time the  Investigator learns of the event. 
 
Deviations involving  the informed consent process or subj ect safety will be r eported 
promptly to Ch esapeake IRB but no l ater than two weeks from the  time of  identifi cation 
of the deviation by the Investigator. 
 
9.9. Safety Reporting to C elgene Corporation 
 
Non-serious adverse events will be  reported to C elgene bi-annually (or upon request by 
Celgene), in a ccordance with 21 CRF  312.64.  
 
When the  Investigator has determin ed that a  SAE  has occurred, the  Investigator is 
responsible for providing info rmation re garding  the SAE  to Celgene in writing using  a 
Celgene SAE form or ME DWATCH 3500A  form of any SAE  within 24 hours of  being 
aware of the event. The  written report must be compl eted and suppli ed to C elgene by 
facsimile within 24 hou rs/1 busin ess day. The initi al report must be  as compl ete as 
possibl e, including an assessment of  the causal relationship betw een the event and the  
invest igational produ ct(s), if  available. Information not  available at the time  of the  
initial report (e.g., an end date for the adverse event or lab oratory values received after 
the report)  must be  document ed on a  follow-up report. A  final report to do cument  
resolution of the SAE is r equired. The Celgene tracking numb er (AX-CL-NSCL C-PI-
004075 ) and the institution al protocol n umber  (LCI-LUN-ABR-001) should be  
includ ed on SAE r eports (or on the fax cover letter) sent to Celgen e. A copy of the  fax 
transmission confirmation of the SAE  report to C elgene  should  be attached to the  SAE 
and r etained with the  patient records. 
 
Celgene Corporation 
Global Drug Safety and Risk Management Connell 
Corporate Park 
300 Connell Drive Suite 6000  
Berkeley Heights, NJ 07922 
Fax number: 908-673-9115 
Email: d r u g s a f e t y @ c e l g e n e.c o m 
 
34 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 Deviations involving  subject safety will be  reported to C elgene prompt ly but no lat er 
than two we eks from the  time of  identifi cation of  the d eviation by the Investigator. 
 
Proto col devi ations th at are minor or administr ative will be  reported to C elgene bi -
annually. 
 
10. TREATMENT -RELA TED ADVERSE EVEN TS 
 
Subje cts will  be closely monitor ed for  treatment-related adverse events.  Adverse event 
monitoring  will o ccur on a continuous b asis for the duration that  subjects are  on stu dy 
therapy.  In addition to the pl anned evaluations during  follow-up visits, subj ects will be 
instru cted to call their  physician to report any adverse events betwe en visits.  
 
10.1. Carboplatin  
 
Anaphylactic reactions h ave occurred with c arboplatin inje ctions.  Adequate medi cal 
supervision must be p resent and appropriate inte rvention must be readily available to 
diagnose and treat hypersensitivi ty reactions.   Bone marrow suppr ession is the dose  
limiting toxicity, and is i ncreased in subjects with imp aired renal function.  It is dose 
dependent. Thrombo cytopen ia with pl atelet 
counts b elow 50 x  109 cells/L occurs in 25% of subjects and  neutropenia with 
granulocyte counts below 1.0 x  109 cells/L occurs in 16% of subj ects.  Anemia is 
cumul ative and transfus ions m ay be necessary in subjects receiving  prolon ged the rapy.  
Cycles should not be repeated until neut rophils and  platelet counts h ave recovered.  
Nausea, vom iting, and neurotoxicity are other  common d rug-related adverse events. 
Other common side  effects of carboplatin in clude n ausea, vomitin g, appetite loss, 
hypokalemia, and hypomagnesemia. 
 
10.2. ABR AXANE 
 
The following  adverse events have  been described with A BRAXANE treatment: 
myelosupp ression, n ausea and vomitin g, diarrhe a, mucositis, in fections, hypotension, 
abnormal ECG changes, cough, dyspnea, edema, s ensory neuropathy, bilirubin/liv er 
enzyme elevations, allergic reactions, alopecia, asthenia, arthralgia, and myalgia. 
During post m arketing surveillance, rare cases of severe hypersensitivity  reactions h ave 
occurred.
35 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
  
Table 10.2.1: Frequencya of Important Tr eatment Emergent Adve rse Events in the 
Randomized Study on a Q3W Schedule 
 ABR AXANE 
260/30 minb 
(% of n=229)  Paclitaxel Injection 
175/3 hc,d 
(% of n=225)  
Bone  Marrow 
Neutrop enia  
80  
82 < 2.0 x  109/L 
< 0.5 x  109/L 9 22 
Thrombo cytopenia  
2  
3 < 100 x  109/L 
< 50 x 109/L <1 <1 
Anemia  
33  
25 < 11 g/Dl 
< 8 g/Dl 1 <1 
Infections  24 20 
Febrile Neutrop enia 2 1 
Bleeding 2 2 
Hypersensitivity Reactione 
All 4 12 
Severef 0 2 
Cardiovas cular 
Vital Si gn Chang esg 
Bradycardia <1 <1 
Hypotension  5 5 
Severe Cardiovascular 
Eventsf 3 4 
Abnormal ECG 
All subj ects 60 52 
Subje cts with No rmal 
Baseline 35 30 
Respira tory 
Cough 7 6 
Dyspnea 12 9 
Sensory  Neuropathy 
Any Symptoms  71 56 
Severe Symptom sf 10 2 
Myalgia / A rthralgia  
Any Symptoms  44 49 
Severe Symptom sf 8 4 
36 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
 Asthenia  
Any Symptoms  47 39 
Severe Symptom sf 8 3 
Fluid Retention/Ed ema 
Any Symptoms  10 8 
Severe Symptom sf 0 <1 
Gastrointestinal  
Nausea   
Any Symptoms  30 22 
Severe Symptom sf 3 <1 
Vomiting  
Any symptoms  18 10 
Severe Symptom sf 4 1 
Diarrhea   
Any Symptoms  27 15 
Severe Symptom sf <1 1 
Mucositis  
Any Symptoms  7 6 
Severe Symptom sf <1 0 
Alop ecia 90 94 
Hepatic  (Subj ects with No rmal Baselin e) 
Bilirubin Elev ations  7 7 
Alkaline Phosph atase 
Elevations  36 31 
AST (SGO T) 
Elevations  39 32 
Injection Site Reaction <1 1 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Based on wo rst grade 
b ABRAXANE dose  in mg/m2/duration in minut es 
c Paclitaxel inje ction do se in mg/m2/duration in hours  
d Paclitaxel-injection subjects received pr emedi cation 
e Includes t reatment-related events related to hypersensitivi ty (e.g., flushi ng, dyspnea,   
chest pain, hypotension)  that b egan on a  day of dosing 
f Severe events are defined as at l east grade 3 toxicity 
g During study drug dosing 
 
10.3. Adve rse Event Characteristics  
 
CTCAE te rm (AE description)  and grade: The descriptions a nd grading scales 
found  in the  revised NCI Common T erminology  Criteria for Adverse Events 
37 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
  
(CTCAE)  version 4.0 wi ll be utili zed for  AE reporting.  All  Levine Ca ncer Institute  
staff will have access to a  copy of the  CTCAE version 4.0. 
 
Attribution of the  AE: 
Definite  – The AE is  clearly related to the  study treatment. 
Prob able – The AE is li kely related to the  study treatment. 
Possible – The AE may  be related to the  study treatment. 
Unlikely – The AE is doubtful ly related to the study treatment. 
Unrelated – The AE is clearly NOT related to the  study treatment. 
 
11. DATA SA FETY AND MONITORING PLAN  
 
11.1. Monito ring 
 
This protocol will be monitored according to the processes in effect for all Levine 
Cancer Institute investigator - initiated studies and the protocol -specific monitoring plan, 
and will abide by standard operating procedures set forth by both the Carolinas 
Healthcare System Office of Clinical and Translational Research and the Levine Cancer 
Institute Clinical Trials Office. It is  the responsibility of the Sponsor -Investigator to 
monitor the safety data for this study. The Sponsor -Investigator, Statistician, Protocol 
Coordinator, and other team members as needed will meet regularly to monitor subject 
consents, enrollment and retent ion, safety data for all subjects [including adverse events 
(AE’s) for all grades and attributions, serious adverse events (SAE’s)], study drug 
administration, and validity/integrity of the data. Documentation of these meetings will 
be kept with study reco rds. SAEs will be reported to the Food and Drug Administration 
(FDA) and the IRB per their requirements. Major protocol deviations that result in a 
threat to subject safety or the integrity of the study will be reported to the FDA  and IRB  
per their require ments. The Sponsor -Investigator will submit data to the LCI Data and 
Safety Monitoring Committee according to the overarching LCI Data and Safety 
Monitoring  Plan.   
 
11.2. Data Quality Assurance 
 
This trial  will be  organized, condu cted, and reported in compli ance with t he protocol, 
standard operating procedures (SOPs) of  LCI and Carolin as Healthcare System O ffice 
of Clinical and Translation al Research, the FDA, and ot her applicable regulations a nd 
guidelines (e.g. GCP).  
 
Subje cts will be  monitor ed by LCI Research /Data Monitors per the study -specific 
monitoring plan and LCI/CHS SOPs for data quality. This monitoring will be done by 
comparing source documentation to the eCRFs. Any variation between the two data sets 
will be discussed with the Protocol Coordinator, Sponsor - Invest igator  and/or other 
study personnel as appropriate.  
38  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
  
The trial database will be  reviewed and checked for omissions, apparent errors, and 
values requiring fu rther clarification usi ng comput erized and manu al procedures. 
Data queries requiri ng clarification will be generated and addressed  as needed by 
appropriate study personnel . Only authorized personn el will m ake corrections to the 
database and all corrections will be do cument ed in an electronic audit tr ail. 
 
12. MEASURE MENT OF  EFFECT  
 
12.1. Antitu mor Effect 
 
Response and progression will be  evaluated in this stu dy using  the revised r esponse 
evaluation c riteria in solid tumo rs (RE CIST) guideline  version 1. 1.16 
 
12.1.1.  Definitions  
 
Evaluable  for toxicity:  All subjects will be  evaluable for toxicity from the time of  
their first tr eatment with A BRAXANE and carbopl atin. 
 
Evaluable  for efficacy:  Only subjects who h ave measurable dis ease present at 
baseline, have received at least one  dose of stu dy therapy, and have had their  
disease re-evaluated (either clinically or radiologically) will be  consid ered evaluable 
for efficacy. These subjects will h ave their obje ctive response  classified according  
to the  definitions stat ed below. 
 
 
 
12.1.2.  Disease Parameters 
 
Target lesions: When more  than one  measurable lesion is pr esent at b aseline all 
lesions up to a  maximum of five lesions tot al (and a maximum of  two lesions per  
organ) representative of all involv ed organs should be identifi ed as target lesions 
and will be  recorded and me asured at baseline. Target lesions should be  selected on 
the basis of th eir size (lesions with the lon gest diameter), be representative of all 
involv ed organs, but in addition should be those  that lend th emselv es to 
reprodu cible repeated measure ments. It may be the case that, on occasion, the 
largest lesion do es not l end its elf to r eproducible measurement in w hich 
circumst ance the n ext largest lesion whi ch can be measured reproducibly should be 
selected. Lymph no des merit spe cial mention since th ey are normal anatomic al 
structures which m ay be visible by imaging even if not involv ed by tumo r. 
Pathological nodes which are  defined as measurable and m ay be identifi ed as target 
lesions must me et the criterion of  a short  axis of ≥ 15 mm by CT scan or M RI. Only 
the short axis of these  nodes will contribute  to the  baseline sum. The  short axis of 
the node  is the diam eter norm ally used by radiolo gists to judge  if a node  is involved 
by solid tumo r. Nod al size is norm ally reported as two dime nsions in the plane  in 
which the  image is obtain ed (for CT s can this is almost alwa ys the axial plan e; for 
39  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
 MRI the plane  of acquisition m ay be axial, sagittal or coronal). The small er of these 
measures is the sho rt axis. All other p atholo gical nodes (those  with short axis ≥ 10 
mm but <15 mm) should be consid ered non-target lesions. Nod es that have  a short 
axis <10  mm are consid ered non-patholo gical and should not be  recorded or 
followed. A sum of the  diam eters (longest for non -nodal lesions, short axis for  
nodal lesions) for all targ et lesions will be  calculated and reported as the baseline  
sum diam eters. If lymph nodes  are to be included in the sum, then as not ed above, 
only the short axis is added into the sum. The  baseline sum diam eters will be  used 
as reference to further characterize any obje ctive tumor  regression in the  measurable 
dimension of the  disease. 
 
Non-target lesions: All other  lesions (or  sites of d isease) including patholo gical 
lymph nod es shou ld be identifi ed as non-target lesions and should also be follow ed 
as ‘present’, ‘absent ’, or in rare cases ‘un equivoc al progression’ (more  details to 
follow ). 
 
12.1.3.  Methods for Eval uation of Measurable Disease  
 
All m easurements should  be taken and recorded in metric not ation using  a ruler or 
calipers. All baseline evaluations should  be performed as closely as possible  to the  
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment. 
 
The same  method of  assessment and the  same  technique should be us ed to 
characterize each identif ied and reported lesion at  baseline and du ring follow -up. 
Imaging-based evaluation is pr eferred to ev aluation by clinical examination wh en 
both m ethods h ave been used to ass ess the  antitumor effect of a  treatment.  The 
Sponso r-Investigator or designee will be r esponsible for performing tumor  
measurements.  The tumor me asurements will be recorded in the  eCRF. 
 
12.1.4.  Response  Criteria 
 
Compl ete Response (CR) : 
Target lesion: Dis appearance of all target lesions.  Any patholo gical lymph nod es 
(whether target or non-target) must h ave reduction in short axis to <10 mm.  
 
Non-target lesion: Dis appearance of all non-target lesions. All lymph nod es must be 
non-pathological in si ze (<10 mm short axis). 
 
Partial Response  (PR): 
Target lesion: At le ast a 30% decrease in the  sum of diam eters of target lesions, 
taking as reference the b aseline sum diam eters. 
 
Non-target lesion: Not applicable  
40  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
 Stable  Disease (SD ): 
Target lesion: N either sufficient shrink age to qua lify for a partial response,  nor 
sufficient incr ease to quali fy for progressive  disease, taki ng as reference the 
small est sum diameters while on stu dy. 
 
Non-target lesion: Not applicable.  
 
Progressive  Disease (PD): 
Target lesion: At le ast a 20% increase in the  sum of diam eters of target lesions, 
taking as reference the small est sum on study (this in cludes the b aseline sum if that 
is the smallest on stu dy). In addition to the relative inc rease of 20%, the sum  must 
also demonstr ate an absolute in crease of at least 5 mm. (Note:  the appearance of 
one or mo re new lesions is also consid ered progression).  
 
Non-target lesion:  Unequivocal progression (as described in RE CIST v ersion 1.1)  
of existing  non-target lesions. ( Note:  the appearance of one or more  new lesions is 
also consid ered progression).  
 
Non-Compl ete Response  / Non -Prog ressive  Disease:  
 
Target lesion: Not applicable 
 
Non-target lesion:  Persistence of one or mo re non-target lesion(s).  
 
  
41  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
 Table 12.1.1:  Summary of RECIST  
 
Target 
Lesions  Non-target Lesions  New  Lesions  Overall 
Respon se Best Respon se for this 
Category also requires 
 
CR  
CR  
No  
CR Documented at least once 
4 weeks from baseline 
CR Non-CR/Non-PD No PR Documented at least once 
PR Non-PD No PR 4 weeks from baseline 
 
SD  
Non-PD  
No  
SD Documented at least once 
4 weeks from baseline 
PD Any Yes or No PD  
 
No prior SD, PR or CR Any PD* Yes or No PD 
Any Any Yes PD 
* In  exceptional  circumstances,  unequivocal  progression  in  non-target  lesions  may  be  accepted  as  disease 
progression. 
 
If nodal disease is included in the sum of t arget lesions and the nod es decrease to 
‘normal’ size (<10 mm), a  measurement may still be r eported on s cans. The  
measurement should be recorded even thou gh the no des are norm al in or der not to 
overstate progression should it be  based on incr ease in si ze of the  nodes. This 
means th at subjects with CR m ay not have a  total sum of the  diam eters of ‘zero’. 
 
Subje cts with a  global d eterioration of  health st atus requiri ng discontinu ation of  
treatment without obj ective eviden ce of disease progression at that time  should be  
reported as ‘symptomatic d eterioration’. Every effort should be made to docum ent 
objective progression even after discontinu ation of  treatment. Symptomatic 
deterioration is  not a descriptor of  an obje ctive response:  it is a reason for  stoppi ng 
study therapy. It is includ ed as part of t he criteria for determination of  Progression 
Free Survival.  The  objective response st atus of su ch subjects is to be d etermined by 
evaluation of t arget and no n-target disease. 
 
For equivocal findi ngs of progression ( e.g. very small and un certain new lesions; 
cystic changes or necrosis in existing lesions), tr eatment may continue  until the  next 
scheduled assessment.  If at the n ext scheduled assessment, p rogression is 
confirmed, the  date of progression should be the earlier date when progression w as 
suspected. 
 
13. STATI STICAL DESI GN 
 
13.1. Sample Si ze Determination 
 
The prim ary objective of this stu dy is to assess the  efficacy in terms of  overall 
tumor  response of  the combin ation of  carbopl atin with na b-paclitaxel in subjects 
with adv anced squamous cell lung cancer.  Subjects will receive six 3-week cycles 
42  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
 of treatment.  The p rimary endpoint  of this stu dy is a bina ry variable d etermined for 
each patient indic ating whether or not th ey achieved an overall tumor  response 
(defined as eith er CR or  PR). 
 
A Bayesian d esign based on predictive p robability will be  implem ented.  This 
design allows  for early stopping  if data indi cates that the treatment is ine ffective. 
The stopping  bound ary is chos en by computing  the predictive probability from 
observed data.  Specifically, the trial will stop  if the  current data  indicates that, by 
the end of  the trial, it is hi ghly unlik ely the 6-cycle best response  rate in t reated 
subjects to be  higher than 0.20.  The specific description of the  methodology  is 
given below. Early treatment discontinuation due to un acceptable  toxicity, PD 
(including  clinical progression) or  death wi ll be consid ered as failures. Other 
subjects not meeting all of the criteria for being included in the efficacy population 
(Section 13.3) will be  consid ered as in-evaluable and therefore will not contribute to 
the sample size of evaluable subjects.  
 
The maximum numb er of evaluable sub jects is N=45.  The  treatment out comes will 
be monitor ed at cohorts of 15,  30 and 45 subj ects.  If X r esponses (CR or PR) h ave 
been obs erved in the  first n  subjects and  Y represents possible numb er of responses 
in the  next (N-n) subjects, the p redictive probability (PP) of concluding a  positive  
result by the end of  the trial is d efined as: 
 
N n 
PP =  i0 {Prob (Y=i) [Prob  (response  rate > 0.20 | X, N, Y=i) > P  
 
T]}. 
43  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
  
The trial will be stopp ed early if PP  < PL, where PT and PL are the parameters to 
be determined to yield d esirable op erating characteristics.  The assumption is that 
the number  of subjects that achieve best respon se of CR or PR follows a  binomial 
distribution with a p robability of p, and p h as a prior distribution  of Beta (0.2, 0.8).  
In addition, the  probability of accepting the new treatment be no larg er than 
0.10 wh en the t rue best response rate is 0.20.  A search algorithm is implem ented to 
find th at PT =0.91 and PL =0.04 s atisfy the constraint and at the same  time 
minim ize the expected sample  size when the t rue best response r ate is 0.2 0. 
 
The following  table lists the  cumul ative number  of subjects (n) and the rejection 
region in the numb er of best responses of  CR or PR in n  subjects. The  trial will be  
stopp ed and the t reatment will be  consid ered ineffective when the number  of 
responses first falls into the rejection re gion. 
 
Table 13.1.1:  Rejection R egion 
N Rejection Re gion in N umber  of 
Responses (CR or PR)  
15 0 – 2 
30 3 – 6 
45 7-12 
 
From a  frequentist perspective, the statisti cal operating characteristics of  the trial 
are given as follows.  Assuming  the true overall response rate is 0.20  under the 
null hypothesis  (i.e. the t rial is ine ffective), then this desi gn will pro vide 8 1% 
power to det ect a di fference of 0.15, or  a true best response r ate is 0.35 un der the 
alternative hypothesi s, assuming  an alpha = 0.09 significance level.  The 
probabilities of  terminating the trial early assumi ng the true best respon se rate is 
0.20 are 0.40 and 0.65 after Stage 1 and St age 2, respe ctively. 
 
To account f or about 1 0% of enrolled patients  not meeting the criteria to be 
included in the efficacy population,  we will accrue about 50 subj ects. 
 
13.2. Analysis E ndpoints 
 
13.2.1.  Primary Efficacy Endpoint 
 
The prim ary endpoint is  a binary variable d etermin ed for  each patient indi cating 
whether or not they achieved a CR or PR  as defined in S ection 
12.1.4.  As per RECIST 1.1, b ecause overall response is the  prim ary endpoint for 
this stu dy, best responses of  CR or PR must be  confirmed by a subsequ ent 
radiolo gic assessment.  
 
 
44  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
 Disease control Disease control is calculated for each subject 
indicating wh ether or not they achieved an ov erall 
response of stable  disease or better. 
Duration of  respon se For subjects who  achieve a CR or PR,  response 
duration will be  measured from the first d ay of the 
respon se until the day on whi ch progressive dise ase 
(PD) or death occurred. The  censori ng method will be  
the same as that d escribed for PFS. 
Duration of  disease 
control For subjects who  achieve SD or  better, dur ation of  
disease control will be  measured from the tre atment 
start date  until the  day on which progressive  
disease (PD)  or de ath oc curred. The censori ng 
method w ill be the s ame as that de scribed for  PFS. 
Progress-free survi val 
(PFS) PFS is de fined as the du ration of  time from treatment 
start date  to time  of progression or  death.  Disease 
progression m ay be determin ed obje ctively as 
described  13.2.2.  Seconda ry Effica cy Endpoi nts 
Table 13.2.1:  Effica cy Endpo int Definitions 
 
45  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
  
 in Section 12.1.4 or  subjectively as determin ed by the 
investi gator.  Evid ence for subjective progressions must 
be document ed in the  medical records.  For objective 
disease progression, the date of PD is the date of the 
radiologic assessment that identified RECIST -defined 
progressive disease. For subjective disease progression, 
the date of PD is the date that the clinician makes the 
determination of dise ase progression. If the subject died 
without documented disease progression, the date of 
progression will be the date of death. For survi ving 
subjects who do not have ob jectively document ed 
disease progression, P FS will be  censored at the date of 
last r adiolo gic assessme nt.  For subjects who receive 
subsequ ent anti -cancer therapy prior  to document ed 
disease progression, P FS will be  censored at the date of 
last r adiolo gic assessme nt prior to the  comm encement of  
subsequ ent therapy.  Subjects who ex perience an initial  
PFS event immediately following 2 or more consecutive 
missed assessments will be censored at the date of  the last 
assessment prior to   those  missed assessment s. For 
participants with only one missed assessment, the 
documented progressive disease status and assessment date 
will be used.  
Overall surviv al (OS) OS is de fined as the du ration of time from tr eatment 
start date to the d ate of death from a ny cause.  Subjects 
who are alive or lost to follow-up at the time of  the 
analysis will be  censored at the last known d ate they 
were alive. 
 
 
13.2.3.  Safety En dpoints 
 
Safety endpoints will include  data for treatment administr ation, adverse events (AEs), 
serious adverse events (SAE s), deaths during  study treatment, and lab oratory 
determinations. A Es and  SAEs will be assess ed according to CTCAE v4 .0. 
 
13.3. Analysis Populations  
 
The efficacy popu lation (or evaluable population)  is defined as all subjects who h ave 
measurable di sease present at b aseline, have received at least one  dose of stu dy therapy, 
and have had their  disease re-evaluated (either clinically or radiographically).  The 
46  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
 efficacy population will be us ed to an alyze the prim ary and secondary efficacy 
endpoints.  
 
The safety population is  defined as all subjects who have received at least one cycle of 
therapy and will be  used to an alyze the saf ety endpoints.  
 
13.4. Timing of Analysis  
 
The first interim futility analysis will occur after the overall response status has been 
determined for 15 evaluable patients, and then a second interim futility analysis will 
occur for 30 evaluable patients, given that the study is not stopped after Stage 1 for 
futility. The primary analysis will be conducted after the overall response has be en 
determined for all 45 evaluable patients, given the study is not stopped after Stage 2 
futility analyses. An updated analysis will be conducted after the overall PFS censoring 
rate reaches 30% or after all surviving patients have at least one year of fo llow up. A 
final analysis will be conducted after the overall survival censoring rate reaches 30% or 
after all surviving patients have at least 3 years of follow up.  
 
 
13.5. Analysis Plan 
 
For the purposes of the primary analysis, the frequency and proportion of  responders 
(those who achieve CR or PR) will be calculated after the best overall response has 
been determined for all patients enrolled in the efficacy population.  A corresponding 
95% confidence interval will be  estimated using  the Clopp er Pears on metho d. 
Hypothesis testing will be done using the rejection regions described in Section 13.1, 
testing the null hypothesis that the ORR is less than 20%. Given the study is not 
stopped early for futility with the interim analyses at 15 and 30 subjects, if there  are at 
least 13 responders in 45 evaluable subjects, the null hypothesis can be rejected.  
For the purposes of the secondary analyses, the frequency and proportion of subjects 
achieving disease control (SD, PR, or CR) will also be calculated along with 
corresponding 95% Clopp er Pears on interval.   For both b est response r ate, and disease 
control rate, the correlation with bas eline subject and dis ease characteristics and 
biom arkers will be  evaluated using  logistic regression.  
Time-to-event variables will be  analyzed usi ng survival analysis methods. Su rvival 
rates will be estimated using  Kaplan-Meier techniques.  The correlation with bas eline 
subject and  disease characteristics,  and biom arkers will be  assessed using  Cox multi ple 
regression models.  
The logistic r egression and Cox  proportional haz ards mod els described above will 
involve  univa riate mode ls to id entify individual p redictive m arkers and multiv ariate 
models (including  backward elimin ation and forward selection) to identi fy independent 
predictive m arkers. 
Biomarkers in both tissue  and blood will be analyzed.  Cor relation among biom arkers in 
tissue, blood and b etween tissue and blood will be assess ed.  The associ ation among 
various continuous and dis crete biom arkers will be assessed first by the exploratory data 
47  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
 analysis using  graphical techniques s uch as the scatter plot mat rix, box plots, and BliP 
plot17. Correlation among  continuous bioma rkers will be  examined by Pearson or 
Spearman rank correlation c oefficients.   The associ ation on dis crete biomarkers will be 
tested by Fisher’s exact test. 
 
 
14. DRUG DISTRIBUTI ON 
 
 
14.1. Supply and D ispensing 
 
ABRAXANE and carboplatin are comm ercially available and will be  locally sour ced, 
prepared, and dispens ed per institutional st andards. Sto rage and handling will comply 
with the  respective package inserts. 
 
14.2. Drug A ccountability  
 
All stu dy medi cations will be stored at the investi gational site in accordance with Good 
Clinic al Practice (GCP) and Good M anufacturing  Practices (GMP) r equirements and 
will be  inaccessible to un author ized personn el. 
An adequate record of t he dispensing  of study drug, and the return of all unused stu dy 
drugs must be k ept in the  form of a  Drug Accountabili ty Form. The  Sponso r-
Investigator, or  responsible p arty designated by the Sponso r-Investigator, will maintain 
a careful record of the  invento ry using the Drug Accountabili ty Form. 
 
15. STU DY COMPLETION  
 
15.1. Completion 
 
The study will be  consid ered compl ete when one or more  of the following conditions  is 
met: 
• All subje cts have  compl eted all stu dy visits in cluding  follow-up. 
• All subje cts have  discon tinued from the stu dy. 
• The IRB, Celgene Corporation, LCI DSMC, or Sponso r-Investigator discontinu es the 
study because of safety consid erations.  
• The Sponsor -Investigator defines an administr ative or clinical cut-off date. 
 
15.2. Termination 
The study will be  termin ated wh en one or mo re of the following  conditions o ccur:  
• If the risk-benefit ratio becomes una cceptable o wing to, for  example: 
• Safety findin gs from this study (e.g. SAE s) 
• Results of any interim analysis 
• Results of p arallel clini cal studies  
48  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
 • Results of p arallel animal studies (e.g. toxicity, teratogeni city, carcinogenicity, 
or reproduction to xicity) 
• If the stu dy condu ct (e.g. recruitm ent rate; dropout rate; data qu ality; protocol 
complian ce) does not sug gest a p roper completion of  the trial within a  
reasonable time frame 
 
The Sponsor -Investigator has the right to close the  trial at any time. For any of the 
above  closures, the following  apply: 
 
 
• Closur es should o ccur only after consultation bet ween involv ed 
parties.  
• All a ffected institutions  must be  informed as applicable a ccording to 
local law. 
• In case of a partial stu dy closur e, ongoing subjects, including  those in 
follow -up, must be cared for in an ethical manner. 
 
Details for  individual subj ect withdr awals can be found in Section 5.3. 
 
16. RETENTION OF  RECOR DS 
 
Document ation of  adverse events, records of study drug receipt and disp ensation, and 
all IRB correspond ence should be retained for at least 2 years after the invest igation is 
compl eted. 
 
17. ETHICAL AND  LEGAL I SSUES 
 
17.1. Ethical and L egal Co nduct of the Study  
 
The proc edures set out in  this proto col, pe rtaining to the  condu ct, ev aluation, and 
document ation of  this stu dy, are designed to ensu re that the  Investigator abide by Good 
Clinic al Practice (GCP) guidelines and un der the guiding  principles detailed in the  Declaration 
of Helsinki.  The study will also be carried out in k eeping with applicable lo cal law(s) and 
regulation(s).  
Document ed approval from app ropriate agencies (e.g. DSMC,  IRB) will be obtain ed for  all 
particip ating centers before start of  the stu dy, according to GCP, loc al laws, regulations and 
organizations.  
Strict adherence to all s pecifications l aid down in  this proto col is r equired for all aspects of 
study conduct; the  Investigators m ay not modi fy or alter the  procedures described in this 
protoco l. 
Modifi cations to the study  protocol  will not be impl ement ed by the Sponsor - Investigator 
without discussion and agreement by Celgene. However, the Investigators m ay impl ement a  
deviation f rom, or  a change of, the  prot ocol to elimin ate an immedi ate hazard(s) to the t rial 
subjects without prior  appro val from applicable ag encies.  As soon as possibl e, the 
impl ement ed deviation or change, the r easons f or it and if appropriate the  proposed  protocol 
amendment should be submitted to the appro priate agencies.  Any deviations f rom the  
49  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
 proto col must be explain ed and do cument ed by the Investigator. 
The Sponso r-Investigator is responsible for the conduct of the  clinical trial at the sit es in 
accordance with  Title  21 of  the Code  of Federal Regulations and/or the D eclaration of  Helsinki.  
The Sponso r-Investigator is responsible for person ally overseeing the t reatment of all study 
subjects. The Sponsor -Investigator must assure  that all stu dy site personn el, including sub-
investi gators and  other study staff  memb ers, adhere to the  study proto col and  all applicable 
regulations and guidelines re garding clinical trials both du ring and after stu dy compl etion. 
The Sponso r-Investigator will be  responsible for assuring  that all the r equired data will 
be collected and properly document ed. 
 
 
17.2. Confidentiality 
 
 
All records id entifying the subject will be k ept co nfidential and, to the  extent p ermitt ed 
by the applicable laws and/or regulations, will not be m ade publi cly available. 
 
18. PUBLIC ATION  POLICY  
 
The Sponso r-Investigator must  send a draft manuscript of the  publi cation or  abstract to 
Celgene Co rporation p rior to subm ission of  the final v ersion for publi cation or  
presentation. All relevant aspects regarding data reporting  and publi cation will be  part 
of the contract betw een Celgene Co rporation and the Sponso r-Investigator. 
 
The Sponso r-Investigator will ensure  that the info rmation r egarding the st udy be 
publi cly available on the  internet at www.clinicaltrials.gov. 
50  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
  
REFEREN CES 
 
1. Siegel R, Ward E, Brawley O, Jemal A. C ancer statistics, 2011: The  impact of 
elimin ating socio economic and ra cial disp arities on prematu re cancer deaths. CA: Cancer 
J Clin 2011;61:21 2-36. 
2. Morg ensztern D, W aqar S, Subr amani an J, Gao F, Govind an R. Improving  surviv al for 
stage IV no n-small cell lung  cancer: a sur veillanc e, epidemiolo gy, and end results surv ey 
from 1990 to 2005. J  Thorac Oncol 2009;4:152 4-9. 
3. Schiller  JH, Harrington D, Belani CP, et al. Compa rison of four chemoth erapy regimens 
for advanced non -small-cell lung  cancer. N Engl J Med 2002;346:9 2-8. 
4. Ibrahim N K, Desai N, Legha S, et al. Phase I and pharmacokinetic stu dy of ABI-007, a 
Cremophor -free, protein-stabili zed, nanoparticle  formulation of  paclitaxel. Clin Can cer 
Res 2002;8:1038 -44. 
5. Gradishar  WJ, Tjul andin S, Davidson N, et al. Ph ase III trial of nanoparticle albumi n- 
bound p aclitaxel comp ared with po lyethylated castor oi l-based paclitaxel in wom en with 
breast cancer. J Clin On col 2005;23:779 4-803. 
6. Nyman DW, Campb ell KJ, Hersh E, et al. Ph ase I and ph armacokinetics tr ial of ABI-007, 
a novel nanoparticle  formulation of  paclitaxel in patients with adv anced nonhematolo gic 
malignancies. J  Clin On col 2005;23:778 5-93. 
7. Blum JL, Savin MA, E delman G, et al. Phase II study of weekly albumi n-bound 
paclitaxel for patients with m etastatic breast cancer heavily pretreated with t axanes. Clin 
Breast Cancer 2007;7:85 0-6. 
8. Robidoux  A, Buzdar AU, Quinaux  E, et al. A ph ase II neoadjuvant tri al of sequential 
nanoparticle albumi n-bound p aclitaxel follow ed by 5- 
fluorouracil/epir ubicin/cyclophosp hamide  in locally advanced breast cancer. Clin Breast 
Cancer 2010;10:8 1-6. 
9. Rizvi NA, Rie ly GJ, Azzoli CG, et al. Ph ase I/II trial of  weekly intravenous  130-nm 
albumin -bound p aclitaxel as initi al chemoth erapy in patients with st age IV non-small -cell 
lung cancer. J Clin On col 2008;26:63 9-43. 
10. Socinski MA, M anikhas GM, Str oyakovs ky DL, et al. A dose  finding  study of weekly 
and every-3-week nab-Paclitaxel follow ed by carboplatin as first-line therapy in patients 
with adv anced non-small cell lung cancer. J Thorac Oncol 2010;5:852 -61. 
11. Socinski MA, Bondarenko IN, Karaseva NA, et al. Survival results of a  randomi zed, 
phase III trial of n ab-paclitaxel and carbopl atin compared with cr emopho r-based 
paclitaxel and carbopl atin as firs t-line therapy in adv anced non-small cell lung cancer. J 
Clin On col, 2011 ASCO  Annu al Meeting Proceedings 2011;29:7551.  
12. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combin ation 
with carbopl atin versus solvent -based paclitaxel plus carbopl atin as first-line therapy in 
patients with advanced non-small -cell lung  lancer: Final results of a  phase III trial. J Clin 
Oncol 2012;30:205 5-62. 
13. Fossella F, Pereira JR, von Pawel J, et al. Random ized, multin ational, phase I II study of 
docetaxel plus pl atinum  combin ations versus vinor elbine  plus cisplatin for advanced non- 
51  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
  
small -cell lung cancer: the TAX  326 stu dy group.  J Clin On col 2003;21:3 016-24. 
14. Sederholm C, Hill erdal G, Lamberg  K, et al. Ph ase III trial of gemcitabine  plus 
carbopl atin versus sin gle-agent gemcitabi ne in the  treatment of loc ally advanced or 
metastatic no n-smal l-cell lung cancer: the  Swedish Lung Cancer Stu dy Group. J  Clin 
Oncol 2005;23:838 0-8. 
15. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Ph armacological effects of formulation 
vehicles : implic ations for  cancer chemoth erapy. Clin Ph armacokinet 2003;42:66 5-85. 
16. Eisenh auer EA, Therasse P, Bogaerts J, et al. New response evaluation c riteria in solid 
tumours: R evised RE CIST guideline  (version 1.1 ). Eur J Cancer 2009;45:22 8-47. 
17. Lee JJ, Tu ZN. A v ersatile one-dimension al distri bution plot:  the BLiP plot. The 
American Statistici an 1997;51:6 3-70. 
18. Desai N, T rieu V, Yao Z, et al: Increased Antitu mor Activity, Intratumor  Paclitaxel 
Concentrations and End othelial C ell Transport of  Cremopho r-Free, Albumin -Bound 
Paclitaxel, AB I-007, C ompared with Cr emopho r-Based Paclitaxel. Clin C ancer Res. 
2006; 12(4 ). 1317 -1324.  
19. Chen, N.,  et al: Ph armacokinetics and Pharmacodynamics of Nab-paclitaxel in Patients 
with Solid Tumors: Dis position Kinetics and Ph armacology Distinct from Solven t-based 
Paclitaxel. The  Journal of Clinic al Pharmacology, 2014. doi: 10.1002/j cph.30 4. 
52  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
  
APPENDICES 
 
APPENDIX A: Performance Status C riteria 
 
 
ECOG Performance Status Scale 
Grade Descriptions  
 
0 Normal activity.  Fully active, able 
to carry on all pre-disease 
performance without restriction.  
 
 
 
 
1 Symptoms, but ambulat ory. 
Restrict ed in p hysically strenuous 
activity, but ambulato ry and able 
to carry out w ork of  a light or 
sedentary nature (e.g., light 
hous ework, office work). 
 
 
 
2 In bed <50% of the time.  
Ambulato ry and capable of all 
self-care, but unab le to carry out 
any work activities.  Up and about 
more  than 50%  of waking hours. 
 
 
3 In bed >50% of the time.  Capable 
of only limited s elf-care, confin ed 
to bed or  chair mo re than 50% of 
waking hours. 
 
 
4 100%  bedridden.  Complet ely 
disabled.  Cannot c arry on any 
self-care.  Total ly confined to bed 
or chair. 
5 Dead. 
53  Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
  
 Required Forms Baseline  During  
Treatment End of 
Treatment Follow-Up 
LCI-LUN-ABR-001: 
Registration/On Stu dy Formg X    
LCI-LUN-ABR-001: M edical 
Histo ry eCRF  X    
Template: Prior Treatment (All) 
eCRF  X    
LCI-LUN-ABR-001: A dverse 
Events eCRF  X Xa X  
Template: Con comitant  
Medications eCRF  X Xa X  
Template: Radiolo gy eCRFf X X X X 
LCI-LUN-ABR-001: Of fice 
Visit eCRF   Xa   
LCI-LUN-ABR-001: Off  
Treatment eCRF    Xb  
Template: Subs equent Treatment 
(All) eCRF     Xe 
Template: Follow-Up eCRF     Xc 
Template: D eath eCRFd     
  
APPENDIX B: Forms Submission  Schedule 
 
Compl ete all el ectronic  case r eport forms in  the CT MS within 10 busin ess days of the visit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Every 3 weeks, ± 7 days. 
b Within 30 days after last dose of study drug. 
c Every 6 months until death or lost to follow-up. 
d At death, regardless of time point. 
e When a subsequent anti-cancer therapy is administered. 
f Every 6 weeks during treatment, and whenever a scan is done thereafter. 
g See Appendix C for hard copy form. 
54 Proto col Numbe r:  LCI-LUN-ABR-001 
Version -2:  November 11, 2015  
 
 
  
 
